# EDGAR Filing Document

**Accession Number:** 0001673985
**File Stem:** 0001673985-25-000135
**Filing Date:** 2025-11
**Character Count:** 177976
**Document Hash:** 16c75ff575227ba251c454fd678a9a15
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001673985-25-000135.hdr.sgml**: 20251107

**ACCESSION NUMBER**: 0001673985-25-000135

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 66

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251107

**DATE AS OF CHANGE**: 20251107

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AdvanSix Inc.
- **CENTRAL INDEX KEY:** 0001673985
- **STANDARD INDUSTRIAL CLASSIFICATION:** PLASTICS, MATERIALS, SYNTH RESINS & NONVULCAN ELASTOMERS [2821]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 812525089
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37774
- **FILM NUMBER:** 251462687

**BUSINESS ADDRESS:**
- **STREET 1:** 300 KIMBALL DRIVE
- **STREET 2:** SUITE 101
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054
- **BUSINESS PHONE:** (973) 526-1800

**MAIL ADDRESS:**
- **STREET 1:** 300 KIMBALL DRIVE
- **STREET 2:** SUITE 101
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054

?xml version='1.0' encoding='ASCII'? asix-20250930

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

---

| | |
|:---|:---|
| (Mark One) | (Mark One) |
| ☒ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

 **For the quarterly period ended September 30, 2025** 

or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _____ to _____**

**Commission File Number: 1-37774**

---

| |
|:---|
| **AdvanSix Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Delaware** | **81-2525089** |
| *(State or other jurisdiction of*<br>*incorporation or organization)* | *(I.R.S. Employer Identification No.)* |

---

---

| | |
|:---|:---|
| **300 Kimball Drive, Suite 101, Parsippany, New Jersey** | **07054** |
| *(Address of principal executive offices)* | *(Zip Code)* |

---

**(973) 526-1800**

*(Registrant's telephone number, including area code)*

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | ASIX | New York Stock Exchange |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes 🗷 No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes 🗷 No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer 🗷 Accelerated filer □ Non-accelerated filer □ Smaller reporting company ☐ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No 🗷

The Registrant had 26,864,035 shares of common stock, $0.01 par value, outstanding at October 31, 2025.

------

**ADVANSIX INC.** 

**FORM 10-Q**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| <u>[Part I.](#i0d1bebfa6b7a428ea6699a63f0919864_10)</u> | <u>[FINANCIAL INFORMATION](#i0d1bebfa6b7a428ea6699a63f0919864_10)</u> | |
| <u>[Item 1.](#i0d1bebfa6b7a428ea6699a63f0919864_13)</u> | <u>[Financial Statements](#i0d1bebfa6b7a428ea6699a63f0919864_13)</u> | <u>[3](#i0d1bebfa6b7a428ea6699a63f0919864_16)</u> |
| | <u>[Condensed Consolidated Statements of Operations for the](#i0d1bebfa6b7a428ea6699a63f0919864_16)</u><u>three and nine months ended September 30, 2025 and 2024</u><u>(unaudited)</u> | <u>[3](#i0d1bebfa6b7a428ea6699a63f0919864_16)</u> |
| | <u>[Condensed Consolidated Statements of Comprehensive Income](#i0d1bebfa6b7a428ea6699a63f0919864_19)[(](#i0d1bebfa6b7a428ea6699a63f0919864_19)[Loss)](#i0d1bebfa6b7a428ea6699a63f0919864_19)[for the](#i0d1bebfa6b7a428ea6699a63f0919864_19)</u><u>three and nine months ended September 30, 2025 and 2024</u><u>[(unaudited)](#i0d1bebfa6b7a428ea6699a63f0919864_19)</u> | <u>[4](#i0d1bebfa6b7a428ea6699a63f0919864_19)</u> |
| | <u>[Condensed Consolidated Balance Sheets as of](#i0d1bebfa6b7a428ea6699a63f0919864_22)September 30, 2025[and](#i0d1bebfa6b7a428ea6699a63f0919864_22)December 31, 2024[(unaudited)](#i0d1bebfa6b7a428ea6699a63f0919864_22)</u> | <u>[5](#i0d1bebfa6b7a428ea6699a63f0919864_22)</u> |
| | <u>[Condensed Consolidated Statements of Cash Flows for the](#i0d1bebfa6b7a428ea6699a63f0919864_25)</u><u>nine months ended September 30, 2025 and 2024</u><u>[(unaudited)](#i0d1bebfa6b7a428ea6699a63f0919864_25)</u> | <u>[6](#i0d1bebfa6b7a428ea6699a63f0919864_25)</u> |
| | <u>[Condensed Consolidated Statements of Stockholders' Equity for the](#i0d1bebfa6b7a428ea6699a63f0919864_28)three and nine months ended September 30, 2025 and 2024[(unaudited)](#i0d1bebfa6b7a428ea6699a63f0919864_28)</u> | <u>[7](#i0d1bebfa6b7a428ea6699a63f0919864_28)</u> |
| | <u>[Notes to Condensed Consolidated Financial Statements (unaudited)](#i0d1bebfa6b7a428ea6699a63f0919864_31)</u> | <u>[9](#i0d1bebfa6b7a428ea6699a63f0919864_31)</u> |
| <u>[Item 2.](#i0d1bebfa6b7a428ea6699a63f0919864_100)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i0d1bebfa6b7a428ea6699a63f0919864_100)</u> | <u>[17](#i0d1bebfa6b7a428ea6699a63f0919864_100)</u> |
| <u>[Item 3.](#i0d1bebfa6b7a428ea6699a63f0919864_157)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i0d1bebfa6b7a428ea6699a63f0919864_157)</u> | <u>[27](#i0d1bebfa6b7a428ea6699a63f0919864_157)</u> |
| <u>[Item 4.](#i0d1bebfa6b7a428ea6699a63f0919864_160)</u> | <u>[Controls and Procedures](#i0d1bebfa6b7a428ea6699a63f0919864_160)</u> | <u>[27](#i0d1bebfa6b7a428ea6699a63f0919864_160)</u> |
| <u>[Part II.](#i0d1bebfa6b7a428ea6699a63f0919864_163)</u> | <u>[OTHER INFORMATION](#i0d1bebfa6b7a428ea6699a63f0919864_163)</u> | <u>[27](#i0d1bebfa6b7a428ea6699a63f0919864_163)</u> |
| <u>[Item 1.](#i0d1bebfa6b7a428ea6699a63f0919864_166)</u> | <u>[Legal Proceedings](#i0d1bebfa6b7a428ea6699a63f0919864_166)</u> | <u>[27](#i0d1bebfa6b7a428ea6699a63f0919864_166)</u> |
| <u>[Item 1A.](#i0d1bebfa6b7a428ea6699a63f0919864_169)</u> | <u>[Risk Factors](#i0d1bebfa6b7a428ea6699a63f0919864_169)</u> | <u>[28](#i0d1bebfa6b7a428ea6699a63f0919864_169)</u> |
| <u>[Item 2.](#i0d1bebfa6b7a428ea6699a63f0919864_172)</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i0d1bebfa6b7a428ea6699a63f0919864_172)</u> | <u>[28](#i0d1bebfa6b7a428ea6699a63f0919864_172)</u> |
| <u>[Item 5.](#i0d1bebfa6b7a428ea6699a63f0919864_175)</u> | <u>[Other Information](#i0d1bebfa6b7a428ea6699a63f0919864_175)</u> | <u>[28](#i0d1bebfa6b7a428ea6699a63f0919864_175)</u> |
| <u>[Item 6.](#i0d1bebfa6b7a428ea6699a63f0919864_181)</u> | <u>[Exhibits](#i0d1bebfa6b7a428ea6699a63f0919864_181)</u> | <u>[29](#i0d1bebfa6b7a428ea6699a63f0919864_181)</u> |
| | <u>[Signature](#i0d1bebfa6b7a428ea6699a63f0919864_184)</u> | <u>[30](#i0d1bebfa6b7a428ea6699a63f0919864_184)</u> |

---

------

**PART I. FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Unaudited)**

**(Dollars in thousands, except share and per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Sales | $374473 | $398187 | $1162286 | $1188495 |
| Costs, expenses and other: |  |  |  |  |
| &nbsp;&nbsp;Costs of goods sold | 349088 | 340885 | 1024716 | 1046860 |
| &nbsp;&nbsp;Selling, general and administrative expenses | 27425 | 24265 | 76250 | 72290 |
| &nbsp;&nbsp;Interest expense, net | 2322 | 2924 | 6119 | 9137 |
| &nbsp;&nbsp;Other non-operating (income) expense, net | (815) | 368 | (1831) | 1808 |
| Total costs, expenses and other | 378020 | 368442 | 1105254 | 1130095 |
| Income (loss) before taxes | (3547) | 29745 | 57032 | 58400 |
| Income tax expense (benefit) | (909) | 7479 | 4955 | 14603 |
| Net income (loss) | $(2638) | $22266 | $52077 | $43797 |
| Earnings per common share |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.10) | $0.83 | $1.94 | $1.63 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.10) | $0.82 | $1.91 | $1.61 |
| Weighted average common shares outstanding |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 26927305 | 26790752 | 26887489 | 26836114 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 26927305 | 27204714 | 27248759 | 27209680 |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

**(Unaudited)**

**(Dollars in thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income (loss) | $(2638) | $22266 | $52077 | $43797 |
| Foreign exchange translation adjustment | (189) | (24) | (154) | (66) |
| Cash-flow hedges |  |  | 7 | 7 |
| Other comprehensive loss, net of tax | (189) | (24) | (147) | (59) |
| Comprehensive income (loss) | $(2827) | $22242 | $51930 | $43738 |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(Unaudited)**

**(Dollars in thousands, except share and per share amounts)**

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| **ASSETS** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $23696 | $19564 |
| &nbsp;&nbsp;Accounts and other receivables – net | 184490 | 145673 |
| &nbsp;&nbsp;Inventories – net | 209120 | 212386 |
| &nbsp;&nbsp;Taxes receivable | 23758 | 503 |
| &nbsp;&nbsp;Other current assets | 13931 | 8990 |
| Total current assets | 454995 | 387116 |
| Property, plant and equipment – net | 943332 | 917858 |
| Operating lease right-of-use assets | 155652 | 153438 |
| Goodwill | 56192 | 56192 |
| Intangible assets | 40857 | 43144 |
| Other assets | 37319 | 37172 |
| Total assets | $1688347 | $1594920 |
| **LIABILITIES** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $236053 | $228761 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 55850 | 47264 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 49 | 1047 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities – short-term | 41695 | 42493 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income and customer advances | 681 | 37538 |
| Total current liabilities | 334328 | 357103 |
| Deferred income taxes | 159758 | 145299 |
| Operating lease liabilities – long-term | 114924 | 111400 |
| Line of credit – long-term | 250000 | 195000 |
| Postretirement benefit obligations | 257 |  |
| Other liabilities | 10848 | 11468 |
| Total liabilities | 870115 | 820270 |
| **COMMITMENTS AND CONTINGENCIES (Note 9)** |  |  |
| **STOCKHOLDERS' EQUITY** |  |  |
| Common stock, par value $0.01; 200,000,000 shares authorized; 33,177,824 shares issued and 26,864,035 outstanding at September 30, 2025; 32,989,165 shares issued and 26,737,036 outstanding at December 31, 2024 | 332 | 330 |
| Preferred stock, par value $0.01; 50,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024 |  |  |
| Treasury stock at par (6,313,789 shares at September 30, 2025; 6,252,129 shares at December 31, 2024) | (63) | (63) |
| Additional paid-in capital | 141876 | 136872 |
| Retained earnings | 670264 | 631541 |
| Accumulated other comprehensive income | 5823 | 5970 |
| Total stockholders' equity | 818232 | 774650 |
| Total liabilities and stockholders' equity | $1688347 | $1594920 |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

**(Dollars in thousands)**

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| Net income | $52077 | $43797 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 58966 | 57197 |
| &nbsp;&nbsp;(Gain) loss on disposal of assets | (177) | 415 |
| &nbsp;&nbsp;Deferred income taxes | 14466 | 3638 |
| &nbsp;&nbsp;Stock-based compensation | 5919 | 5963 |
| &nbsp;&nbsp;Amortization of deferred financing fees | 464 | 464 |
| &nbsp;&nbsp;Operational asset adjustments |  | 1200 |
| &nbsp;&nbsp;Changes in assets and liabilities, net of business acquisitions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and other receivables | (38971) | 15069 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 3266 | (1603) |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes receivable | (23255) | 1059 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 16546 | (43687) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | (998) | (7598) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 8913 | 10988 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income and customer advances | (36857) | (14161) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | (1218) | (1493) |
| Net cash provided by operating activities | 59141 | 71248 |
| **Cash flows from investing activities:** |  |  |
| Expenditures for property, plant and equipment | (88849) | (99373) |
| Other investing activities | (6153) | (6053) |
| Net cash used for investing activities | (95002) | (105426) |
| **Cash flows from financing activities:** |  |  |
| Borrowings from line of credit | 316500 | 311500 |
| Repayments of line of credit | (261500) | (266500) |
| Principal payments of finance leases | (740) | (762) |
| Dividend payments | (12876) | (12858) |
| Purchase of treasury stock | (1658) | (10427) |
| Issuance of common stock | 267 | 755 |
| Net cash provided by financing activities | 39993 | 21708 |
| Net change in cash and cash equivalents | 4132 | (12470) |
| Cash and cash equivalents at beginning of period | 19564 | 29768 |
| Cash and cash equivalents at the end of period | $23696 | $17298 |
| Supplemental non-cash investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures included in accounts payable | $14894 | $15018 |
| Supplemental cash activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $4268 | $7711 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes | $15201 | $19019 |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(Unaudited)**

**(Dollars in thousands)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| | **Shares** | **Amount** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| **Balance at December 31, 2024** | 32989165 | $330 | $136872 | $631541 | $(63) | $5970 | $774650 |
| Net income |  |  |  | 23344 |  |  | 23344 |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | 11 | 11 |
| &nbsp;&nbsp;Cash-flow hedges |  |  |  |  |  | 7 | 7 |
| Other comprehensive income, net of tax |  |  |  |  |  | 18 | 18 |
| Issuance of common stock | 124214 | 1 | 153 |  |  |  | 154 |
| Purchase of treasury stock (53,432 shares) |  |  | (1486) |  |  |  | (1486) |
| Stock-based compensation |  |  | 1978 |  |  |  | 1978 |
| Dividends |  |  | 160 | (4450) |  |  | (4290) |
| **Balance at March 31, 2025** | **33113379** | **331** | **137677** | **650435** | **(63)** | **5988** | **794368** |
| Net income |  |  |  | 31371 |  |  | 31371 |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | 24 | 24 |
| Other comprehensive loss, net of tax |  |  |  |  |  | 24 | 24 |
| Issuance of common stock | 38907 | 1 |  |  |  |  | 1 |
| Purchase of treasury stock (2,538 shares) |  |  | (51) |  |  |  | (51) |
| Stock-based compensation |  |  | 2309 |  |  |  | 2309 |
| Dividends |  |  | 162 | (4452) |  |  | (4290) |
| **Balance at June 30, 2025** | **33152286** | **332** | **140097** | **677354** | **(63)** | **6012** | **823732** |
| Net income |  |  |  | (2638) |  |  | (2638) |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | (189) | (189) |
| Other comprehensive loss, net of tax |  |  |  |  |  | (189) | (189) |
| Issuance of common stock | 25538 |  | 112 |  |  |  | 112 |
| Purchase of treasury stock (5,690 shares) |  |  | (121) |  |  |  | (121) |
| Stock-based compensation |  |  | 1632 |  |  |  | 1632 |
| Dividends |  |  | 156 | (4452) |  |  | (4296) |
| **Balance at September 30, 2025** | **33177824** | $**332** | $**141876** | $**670264** | $**(63)** | $**5823** | $**818232** |

---

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(Unaudited)**

**(Dollars in thousands)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| | **Shares** | **Amount** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| **Balance at December 31, 2023** | 32598946 | $326 | $138046 | $605067 | $(58) | $(4144) | $739237 |
| Net loss |  |  |  | (17396) |  |  | (17396) |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | (15) | (15) |
| &nbsp;&nbsp;Cash-flow hedges |  |  |  |  |  | 7 | 7 |
| Other comprehensive loss, net of tax |  |  |  |  |  | (8) | (8) |
| Issuance of common stock | 323989 | 3 | 423 |  |  |  | 426 |
| Purchase of treasury stock (260,464 shares) |  |  | (7020) |  | (3) |  | (7023) |
| Stock-based compensation |  |  | 2211 |  |  |  | 2211 |
| Dividends |  |  | 163 | (4453) |  |  | (4290) |
| **Balance at March 31, 2024** | **32922935** | **329** | **133823** | **583218** | **(61)** | **(4152)** | **713157** |
| Net income |  |  |  | 38927 |  |  | 38927 |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | (27) | (27) |
| Other comprehensive loss, net of tax |  |  |  |  |  | (27) | (27) |
| Issuance of common stock | 36653 | 1 |  |  |  |  | 1 |
| Purchase of treasury stock (141,242 shares) |  |  | (3360) |  | (2) |  | (3362) |
| Stock-based compensation |  |  | 2193 |  |  |  | 2193 |
| Dividends |  |  | 130 | (4422) |  |  | (4292) |
| **Balance at June 30, 2024** | **32959588** | **330** | **132786** | **617723** | **(63)** | **(4179)** | **746597** |
| Net income |  |  |  | 22266 |  |  | 22266 |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | (24) | (24) |
| Other comprehensive loss, net of tax |  |  |  |  |  | (24) | (24) |
| Issuance of common stock | 23280 |  | 328 |  |  |  | 328 |
| Purchase of treasury stock (1,948 shares) |  |  | (42) |  |  |  | (42) |
| Stock-based compensation |  |  | 1559 |  |  |  | 1559 |
| Dividends |  |  | 104 | (4380) |  |  | (4276) |
| **Balance at September 30, 2024** | **32982868** | $**330** | $**134735** | $**635609** | $**(63)** | $**(4203)** | $**766408** |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

**1. Organization, Operations and Basis of Presentation**

***Description of Business***

AdvanSix Inc. ("AdvanSix," the "Company," "we" or "our") is a diversified chemistry company that produces essential materials for our customers in a wide variety of end markets and applications that touch people's lives. Our integrated value chain of our five U.S.-based manufacturing facilities plays a critical role in global supply chains and enables us to innovate and deliver essential products for our customers across building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, electronics and other end markets. Guided by our core values of Safety, Integrity, Accountability and Respect, AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, plant nutrients, and chemical intermediates.

***Basis of Presentation***

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of September 30, 2025, and its results of operations for the three and nine months ended September 30, 2025 and 2024 and cash flows for the nine months ended September 30, 2025 and 2024. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year. These financial statements should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2024. All intercompany transactions have been eliminated.

Certain prior period amounts have been reclassified for consistency with the current period presentation.

It is our practice to establish actual quarterly closing dates using a predetermined fiscal calendar, which requires our businesses to close their books on a Saturday in order to minimize the potentially disruptive effects of quarterly closing on our business processes. Historically, the effects of this practice have generally not been significant to reported results for any quarter and only existed within a reporting year. In the event that differences in actual closing dates are material to year-over-year comparisons of quarterly or year-to-date results, we will provide the appropriate disclosures. Our actual closing dates for the three and nine months ended September 30, 2025 and 2024 were September 27, 2025 and September 28, 2024, respectively.

Liabilities to creditors to whom we have issued checks that remained outstanding at September 30, 2025 and December 31, 2024 aggregated to $6.4 million and $7.3 million, respectively. These were included in Cash and cash equivalents and Accounts payable in the Condensed Consolidated Balance Sheets.

The Company previously reported a business impact associated with the June 2019 fire that shut down the Philadelphia Energy Solutions refinery in Philadelphia, Pennsylvania. The Company actively pursued a business interruption claim and reached a final omnibus settlement in January 2025 which resulted in insurance settlement proceeds of approximately $26 million in the first quarter of 2025. The total aggregate insurance proceeds since the original claim submission are approximately $39 million. The proceeds have been recognized as a reduction to Costs of Goods Sold on the Condensed Consolidated Statements of Operations in the periods in which they were received.

As of September 30, 2025, the Company has repurchased a total of 6,313,789 shares of common stock, including 1,068,333 shares withheld to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $194.1 million at a weighted average market price of $30.74 per share. As of September 30, 2025, approximately $62.0 million remained available for share repurchases under the current authorization approved by the Company's Board of Directors (the "Board") on February 17, 2023. During the period October 1, 2025 through October 31, 2025, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions,

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.

**2. Recent Accounting Pronouncements**

**Recent Accounting Pronouncements** – The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued by the Financial Accounting Standards Board ("FASB"). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations.

In August 2025, the FASB issued ASU 2025-05, Financial Instruments – Credit Losses (Topic 326): Practical Expedient for Measuring Expected Credit Losses on Certain Financial Assets. The amendments in this ASU provide a simplified approach for estimating credit losses on certain financial assets, including current accounts receivable, by permitting entities to elect a practical expedient when measuring expected credit losses. Under current guidance, when estimating expected credit losses, an entity must (1) consider not only historical loss experience but also adjust that information to reflect current conditions and reasonable and supportable forecasts and (2) include a measure of expected credit loss even if that risk is remote. The amendments in this ASU allow an entity, as a practical expedient, to: (1) Assume that current conditions as of the balance sheet date will remain unchanged over the remaining life of the financial asset; and (2) continue to adjust historical loss information to reflect current conditions to the extent that historical information does not already do so. The amendments are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual periods. Early adoption is permitted in any interim or annual period for which financial statements have not yet been issued or made available for issuance. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in this ASU require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses. The amendments require that at each interim and annual reporting period an entity will: (1) disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and (e) depreciation, depletion, and amortization recognized as part of oil-and gas-producing activities (or other amounts of depletion expense) included in each relevant expense caption. A relevant expense caption is an expense caption presented on the face of the income statement within continuing operations that contains any of the expense categories listed in (a)-(e); (2) include certain amounts that are already required to be disclosed under current generally accepted accounting principles (GAAP) in the same disclosure as other disaggregation requirements; (3) disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) disclose the total amount of selling expense and, in annual reporting periods, an entity's definition of selling expense. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendments in this ASU should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the pronouncement and does not expect adoption to have a material impact on the Company's consolidated financial position or results of operations.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this ASU require that public business entities, on an annual basis, disclose specific categories in the rate reconciliation and provide additional information for reconciling items that are equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate. The amendments also require that the Company disclose the following (net of refunds received): (1) the amount of income taxes paid disaggregated by federal (national), state, and foreign taxes and (2) the amount of income taxes paid disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5 percent of total income taxes paid. Additionally, the amendments in this update eliminate the requirement for all entities to disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12 months or to make a statement that an estimate of the range cannot be made, and remove the requirement to disclose the cumulative amount of each type of temporary difference when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries and corporate joint ventures. This pronouncement is effective for annual periods beginning after December 31, 2024 and the required disclosures will be adopted in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

**3. Revenues**

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

***Revenue Recognition***

AdvanSix serves around 390 customers annually, primarily in the United States, spanning a wide variety of industries worldwide. For the nine months ended September 30, 2025 and 2024, the Company's ten largest customers accounted for approximately 41% and 38% of total sales, respectively.

We typically sell to customers under master service agreements, with primarily one-year terms, or by purchase orders. We have historically experienced low customer turnover and have long-standing customer relationships, which span decades. Our largest customer is Shaw Industries Group, Inc. ("Shaw"), a significant consumer of caprolactam and Nylon 6 resin, to whom we sell under a long-term agreement. For the three months ended September 30, 2025 and 2024, the Company's sales to Shaw were 12% and 10% of our total sales, respectively. For the nine months ended September 30, 2025 and 2024, the Company's sales to Shaw were 10% and 9% of our total sales, respectively.

The Company's revenue by product line, and related approximate percentage of total sales, for the three and nine months ended September 30, 2025 and 2024 were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2025** | **2024\*** | **2024\*** | **2025** | **2025** | **2024\*** | **2024\*** |
| Nylon | $79029 | 21% | $93693 | 24% | $246900 | 21% | $281299 | 24% |
| Caprolactam | 73137 | 20% | 76338 | 19% | 206993 | 18% | 219117 | 18% |
| Plant Nutrients | 138661 | 37% | 113552 | 29% | 423672 | 36% | 355587 | 30% |
| Chemical Intermediates | 83646 | 22% | 114604 | 28% | 284721 | 25% | 332492 | 28% |
| Total | $374473 | 100% | $398187 | 100% | $1162286 | 100% | $1188495 | 100% |

---

*\* The Company transferred certain products between its Chemical Intermediates product line and its Plant Nutrients product line to align more closely with its current sales structure. Historical information has been reclassified to reflect these changes for all periods presented in the Consolidated Financial Statements. Total revenue amounts were not impacted for either period.*

The Company's revenues by geographic area, and related approximate percentage of total sales, for the three and nine months ended September 30, 2025 and 2024 were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| United States | $323746 | 86% | $339895 | 85% | $1002864 | 86% | $1026342 | 86% |
| International\* | 50727 | 14% | 58292 | 15% | 159422 | 14% | 162153 | 14% |
| Total | $374473 | 100% | $398187 | 100% | $1162286 | 100% | $1188495 | 100% |

---

*\* Predominantly Latin America and Canada.*

***Deferred Income and Customer Advances***

The Company defers revenues when cash payments are received in advance of our performance. Below is a roll-forward of Deferred income and customer advances for the nine months ended September 30, 2025:

---

| | |
|:---|:---|
| Opening balance January 1, 2025 | $37538 |
| Additional cash advances | 101 |
| Less amounts recognized in revenues | (36958) |
| Ending balance September 30, 2025 | $681 |

---

The Company expects to recognize as revenue the September 30, 2025 ending balance of Deferred income and customer advances within one year or less.

**4. Earnings Per Share**

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

The computation of basic and diluted earnings per share ("EPS") is based on Net income (loss) divided by the basic weighted average number of common shares outstanding and, where appropriate, diluted weighted average number of common shares outstanding, respectively. The details of the basic and diluted EPS calculations for the three and nine months ended September 30, 2025 and 2024 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Basic** |  |  |  |  |
| Net income (loss) | $(2638) | $22266 | $52077 | $43797 |
| Weighted average common shares outstanding | 26927305 | 26790752 | 26887489 | 26836114 |
| EPS – Basic | $(0.10) | $0.83 | $1.94 | $1.63 |
| **Diluted** |  |  |  |  |
| Dilutive effect of equity awards and other stock-based holdings |  | 413962 | 361270 | 373566 |
| Weighted average common shares outstanding | 26927305 | 27204714 | 27248759 | 27209680 |
| EPS – Diluted | $(0.10) | $0.82 | $1.91 | $1.61 |

---

Where appropriate, diluted EPS is computed based upon the weighted average number of common shares outstanding for the period plus the dilutive effect of common stock equivalents using the treasury stock method and the average market price of our common stock for the period.

Where appropriate, the diluted EPS calculations exclude the effect of stock options when the options' assumed proceeds exceed the average market price of the common shares during the period. The anti-dilutive common stock equivalents outstanding at the three and nine months ended September 30, 2025 and 2024 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Options and stock equivalents | 934424 | 573586 | 973713 | 976699 |

---

Dividend activity for the three and nine months ended September 30, 2025 and 2024 was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Cash dividends declared per share | $0.16 | $0.16 | $0.48 | $0.48 |
| Aggregate dividends paid to shareholders | $4296 | $4276 | $12876 | $12858 |

---

**5. Accounts and Other Receivables** – **Net**

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Accounts receivables | $183940 | $141273 |
| Other | 911 | 4982 |
| Total accounts and other receivables | 184851 | 146255 |
| Less – allowance for credit losses | (361) | (582) |
| Total accounts and other receivables – net | $184490 | $145673 |

---

**6. Inventories**

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

---

| | | |
|:---|:---|:---|
| | **September 30,<br>2025** | **December 31,<br>2024** |
| Raw materials | $91366 | $99320 |
| Semi-finished and finished goods | 164373 | 145169 |
| Spares and other | 33509 | 31948 |
|  | 289248 | 276437 |
| Reduction to LIFO cost basis | (80128) | (64051) |
| Total inventories | $209120 | $212386 |

---

Substantially all of the Company's inventories at September 30, 2025 and December 31, 2024 are valued at the lower of cost or market using the last-in, first-out ("LIFO") method. However, approximately 6% was valued at average cost using the first-in, first-out ("FIFO") method at September 30, 2025.

The excess of replacement cost over the carrying value of total inventories subject to LIFO was $78.2 million and $57.5 million at September 30, 2025 and December 31, 2024, respectively.

**7. Leases**

The Company determines if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use assets ("ROU"), Operating lease liabilities – short-term, and Operating lease liabilities – long-term in our Condensed Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment – net, Accounts payable, and Other liabilities in our Condensed Consolidated Balance Sheets.

The components of lease expense were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Finance lease cost: |  |  |  |  |
| &nbsp;&nbsp;Amortization of right-of-use asset | $245 | $269 | $748 | $776 |
| &nbsp;&nbsp;Interest on lease liabilities | 34 | 43 | 113 | 120 |
| &nbsp;&nbsp;Total finance lease cost | 279 | 312 | 861 | 896 |
| Operating lease cost | 14111 | 10305 | 40721 | 32789 |
| Short-term lease cost | 963 | 1177 | 2579 | 3511 |
| Total lease cost | $15353 | $11794 | $44161 | $37196 |

---

As of September 30, 2025, we have no additional operating or finance leases that have not yet commenced.

**8. Goodwill and Intangible Assets**

Intangible assets with finite lives acquired through a business combination are recorded at fair value, less accumulated amortization. Customer relationships and trade-names are amortized on a straight-line basis over their expected useful lives of 15 to 20 years and 5 years, respectively.

*<u>Goodwill</u>*

There was no change in the carrying amount of goodwill for the nine months ended September 30, 2025.

*<u>Finite-Lived Intangible Assets</u>*

Intangible assets subject to amortization were as follows:

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Book Value** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Book Value** |
| Customer relationships | $36820 | $(7096) | $29724 | $36820 | $(5666) | $31154 |
| Licenses | 18451 | (7611) | 10840 | 18451 | (6919) | 11532 |
| Trade names | 1100 | (807) | 293 | 1100 | (642) | 458 |
| &nbsp;&nbsp;Total | $56371 | $(15514) | $40857 | $56371 | $(13227) | $43144 |

---

For each of the three months ended September 30, 2025 and September 30, 2024, the Company recorded amortization expense on intangible assets of $0.8 million. For each of the nine months ended September 30, 2025 and September 30, 2024, the Company recorded amortization expense on intangible assets of $2.3 million.

**9. Commitments and Contingencies**

The Company is subject to a number of lawsuits, investigations and disputes, some of which may involve substantial amounts claimed, arising out of the conduct of the Company or other third-parties in the normal and ordinary course of business. A liability is recognized for any contingency that is probable of occurrence and reasonably estimable. The Company continually assesses the likelihood of adverse judgments or outcomes in these matters, as well as potential ranges of possible losses, based on an analysis of each matter with the assistance of legal counsel and, if applicable, other experts.

Given the uncertainty inherent in such lawsuits, investigations and disputes, the Company does not believe it is possible to develop estimates of reasonably possible loss in excess of current accruals for these matters. Considering the Company's past experience and existing accruals, the Company does not expect the outcome of these matters, either individually or in the aggregate, to have a material adverse effect on the Company's consolidated financial position or results of operations. Potential liabilities are subject to change due to new developments, changes in settlement strategy or the impact of evidentiary requirements, which could cause the Company to pay damage awards or settlements (or become subject to equitable remedies) that could have a material adverse effect on the Company's consolidated results of operations, balance sheet and/or operating cash flows in the periods recognized or paid.

We assumed from Honeywell International Inc. ("Honeywell") all health, safety and environmental ("HSE") liabilities and compliance obligations related to the past and future operations of our current business, as well as all HSE liabilities associated with the three manufacturing locations assumed from Honeywell that are used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to have a material adverse effect on the Company's consolidated financial position or results of operations.

**10. Income Taxes**

The provision (benefit) for income taxes was ($0.9 million) and $7.5 million for the three months ended September 30, 2025 and 2024, respectively, resulting in an effective tax rate of 25.6% and 25.1%, respectively. The provision for income taxes was $5.0 million and $14.6 million for the nine months ended September 30, 2025 and 2024, respectively, resulting in an effective tax rate of 8.7% and 25%, respectively.

The Company's provision (benefit) for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income (loss) before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The Company's effective tax rate for the three and nine months ended September 30, 2025 and 2024 differed from the U.S. federal statutory rate due to state taxes and executive compensation deduction limitations which generally increase the rate, offset by research tax credits and the foreign-derived intangible income deduction that generally decrease the rate. During the nine months ended September 30, 2025, discrete tax adjustments recorded relating to Internal Revenue Code (IRC) Section 45Q tax credits of $9.7 million and return to provision adjustments related to the filing of the Company's 2024 U.S. federal income tax return of $0.2 million, offset slightly by state tax legislation changes and the vesting of equity compensation, resulted in a net 5% increase and 17% decrease to the estimated annual effective tax rate for the three and nine months ended

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

September 30, 2025, respectively. In 2024, the Company recorded discrete tax adjustments related to the vesting of equity compensation, changes to state tax legislation, and return to provision adjustments related to the filing of the Company's 2023 U.S. federal income tax return which resulted in a net 3.3% and 1.5% increase to the estimated annual effective tax rate for the three and nine months ended September 30, 2024, respectively.

On July 4, 2025, President Trump signed into law legislation commonly referred to as the One Big Beautiful Bill Act (the "Act"), which includes numerous tax provisions affecting businesses, including the reinstatement of full expensing of domestic research and experimental expenditures, modification of the limitation on business interest and making permanent full expensing for certain business property. These provisions resulted in an approximate $10 million reduction in cash taxes in our financial results for the three and nine months ended September 30, 2025, however due to the elective applicability of these provisions, we continue to evaluate the full impact and timing that these provisions will have on our financial results.

**11. Supplier Finance Programs**

The Company has entered into a supply chain finance program with a financial intermediary providing participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. AdvanSix's responsibility is limited to making payments to the intermediary based upon payment terms negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. The Company's payment terms with suppliers are consistent, regardless of whether a vendor participates in the supply chain finance program or not. All related agreements are terminable by either party upon at least 30 days' notice.

The total amount due to the financial intermediary to settle supplier invoices under the Company's supply chain finance program was approximately $5.8 million as of September 30, 2025 and approximately $19.2 million as of December 31, 2024. These amounts outstanding are included in Accounts payable.

**12. Segment Related Information**

The Company has concluded that it is a single operating segment and a single reportable segment: chemical manufacturing. Its larger manufacturing sites are vertically integrated and leverage cross-plant resources, including centralized supply chain and procurement functions. This production process uses one key raw material, cumene, as the input to products produced for sale through the sales channels and end markets the Company serves. Production rates and output volumes are managed across locations to align with the Company's overall operating plan. Additionally, the Company's operating results, which are evaluated regularly to make decisions about resource allocation and performance assessment by the chief operating decision maker ("CODM"), our CEO and President, are on a consolidated basis.

The chemical manufacturing segment derives its revenues by innovating and delivering essential products in the industries of nylon solutions, plant nutrients, and chemical intermediates to its customers in a wide variety of end markets and applications, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics.

The CODM's performance assessment and resource allocation for the chemical manufacturing segment is based on net income which is also reported on the income statement as net income, the measure of segment assets which is also reported on the balance sheet as total assets, and capital expenditures which is also reported in management's discussion and analysis.

The CODM uses net income generated from segment assets in deciding whether to reinvest profits into the segment or into other parts of the entity, such as for acquisitions or to pay dividends. The CODM also uses net income to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management's compensation. Lastly, the CODM uses capital expenditures to estimate the cash-generating potential and cash requirements of the segment.

Significant expense information reviewed by the CODM was as follows (in thousands):

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue | $374473 | $398187 | $1162286 | $1188495 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;Variable costs of goods sold \* | 181899 | 177679 | 509980 | 553199 |
| &nbsp;&nbsp;Plant costs | 121861 | 115059 | 371090 | 350458 |
| &nbsp;&nbsp;Freight and distribution costs | 42769 | 45871 | 136385 | 136041 |
| &nbsp;&nbsp;Selling, general, and administrative expense | 27425 | 24265 | 76250 | 72290 |
| &nbsp;&nbsp;Other segment items \*\* | 3157 | 13047 | 16504 | 32710 |
| Segment net income (loss) | $(2638) | $22266 | $52077 | $43797 |

---

*\*Variable costs of goods sold includes the raw material costs associated with volumes sold during the period as well as insurance settlement proceeds, when applicable.*

*\*\*Other segment items include research and development expense, interest income and expense, capitalized interest, other non-operating expense, and income tax expense.*

**13. Subsequent Events**

*<u>Dividends</u>*

As announced on November 7, 2025, the Board declared a quarterly cash dividend of $0.16 per share on the Company's common stock, payable on December 2, 2025 to stockholders of record as of the close of business on November 18, 2025.

*<u>Amendment to Credit Agreement</u>*

On October 23, 2025, the Company entered into Amendment No. 2 (the "Amendment") to the Credit Agreement, dated as of October 27, 2021 (as amended by Amendment No. 1, dated June 27, 2023, the "Credit Agreement" and as further amended by the Amendment, the "Amended Credit Agreement"), among the Company, the guarantors, the lenders party thereto and Truist Bank, as administrative agent.

The Credit Agreement includes a senior secured revolving credit facility with aggregate commitments of $500 million (the "Revolving Credit Commitments"). Pursuant to the Amendment, the Credit Agreement was amended to, among other things: (i) extend the maturity date of revolving credit commitments of participating Revolving Credit Lenders in an aggregate principal amount of $452 million to the earlier of (x) October 27, 2027 and (y) the date of the termination in whole of the Revolving Credit Commitments, pursuant to the terms of the Amended Credit Agreement, and (ii) effect certain other conforming changes and modifications consistent with the foregoing. The remaining $48 million of revolving credit commitments under the Credit Agreement that were not extended will continue to mature on the earlier of (x) October 27, 2026 and (y) the date of the termination in whole of the Revolving Credit Commitments, pursuant to the terms of the Amended Credit Agreement.

------

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion and analysis of the financial condition and results of operations, of AdvanSix Inc. ("AdvanSix," the "Company," "we" or "our"), which we refer to as our "MD&A," should be read in conjunction with the Condensed Consolidated Financial Statements and the notes thereto contained in this Quarterly Report on Form 10-Q (this "Form 10-Q"), as well as the MD&A section included in our Annual Report on Form 10-K for the year ended December 31, 2024 ("2024 Form 10-K"). Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a number of factors that can affect our performance in both the near- and long-term, including those incorporated by reference in Item 1A of Part II of this Form 10-Q as such factors may be revised or supplemented in subsequent filings with the SEC, as well as those discussed in the section entitled "Note Regarding Forward-Looking Statements" below.

**Note Regarding Forward-Looking Statements**

All statements other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this MD&A regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements within the meaning of Section 21E of the Exchange Act. When used in this Form 10-Q, words such as "expect," "anticipate," "estimate," "outlook," "project," "strategy," "intend," "plan," "target," "goal," "may," "will," "should," and "believe," and other variations or similar terminology and expressions identify forward-looking statements. Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties and other factors, many of which are beyond our control and difficult to predict, which may cause the actual results or performance of the Company to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: general economic and financial conditions in the U.S. and globally; the potential effects of inflationary pressures, tariffs or the imposition of new tariffs, trade wars, barriers or restrictions, or threats of such actions, changes in interest rates, labor market shortages and supply chain issues; instability or volatility in financial markets or other unfavorable economic or business conditions caused by geopolitical concerns, including as a result of new or proposed legislation or regulatory, trade or other policies in or impacting the U.S., the U.S. government shutdown, the conflict between Russia and Ukraine, the conflicts in Israel, Gaza and Iran, and related instability in the surrounding region, and the uncertain outcomes of such conflicts; the effect of any of the foregoing on our customers' demand for our products and our suppliers' ability to manufacture and deliver our raw materials, including implications of reduced refinery utilization in the U.S.; our ability to sell and provide our goods and services; the ability of our customers to pay for our products; any closures of our and our customers' offices and facilities; risks associated with increased phishing, compromised business emails and other cybersecurity attacks, data privacy incidents and disruptions to our technology infrastructure; risks associated with operating with a reduced workforce; risks associated with our indebtedness including compliance with financial and restrictive covenants, and our ability to access capital on reasonable terms, at a reasonable cost, or at all, due to economic conditions or otherwise; the impact of scheduled turnarounds and significant unplanned downtime and interruptions of production or logistics operations as a result of mechanical issues or other unanticipated events such as fires, severe weather conditions, natural disasters, pandemics, geopolitical conflicts and related events; price fluctuations, cost increases and supply of raw materials; our operations and growth projects requiring substantial capital; growth rates and cyclicality of the industries we serve including global changes in supply and demand; failure to develop and commercialize new products or technologies; loss of significant customer relationships; adverse trade and tax policies; extensive environmental, health and safety laws that apply to our operations; hazards associated with chemical manufacturing, storage and transportation; litigation associated with chemical manufacturing and our business operations generally; inability to acquire and integrate businesses, assets, products or technologies; protection of our intellectual property and proprietary information; prolonged work stoppages as a result of labor difficulties or otherwise; failure to maintain effective internal controls; our ability to declare and pay quarterly cash dividends and the amounts and timing of any future dividends; our ability to repurchase our common stock and the amount and timing of any future repurchases; disruptions in supply chain, transportation and logistics; potential for uncertainty regarding qualification for tax treatment of our spin-off; fluctuations in our stock price; and changes in laws or regulations applicable to our business. Forward-looking statements are not guarantees of future performance and actual results could differ materially from those contemplated by the forward-looking statements as a result of a number of risks, uncertainties and other factors including those noted above and those detailed in Item 1A of Part I and elsewhere in our 2024 Form 10-K, and subsequent reports filed with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We do not undertake to update or revise any of our forward-looking statements.

**Business Overview**

AdvanSix is a diversified chemistry company that produces essential materials for our customers in a wide variety of end markets and applications that touch people's lives. Our integrated value chain of our five U.S.-based manufacturing facilities plays a critical role in global supply chains and enables us to innovate and deliver essential products for our customers across

------

building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, electronics and other end markets. Guided by our core values of Safety, Integrity, Accountability and Respect, AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, plant nutrients, and chemical intermediates. Our key product lines are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;**• Nylon Solutions**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**◦ Nylon –** We sell our Nylon 6 resin globally, primarily under the Aegis® brand name. Nylon 6 is a polymer resin which is a synthetic material used by our customers to produce fibers, filaments, engineered plastics and films that, in turn, are used in such end-products as carpets, automotive and electric components, sports apparel, food packaging and other industrial applications.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ **Caprolactam –** Caprolactam is the key monomer used in the production of Nylon 6 resin. We internally polymerize caprolactam into Aegis® Nylon 6 Resins, and we also market and sell the caprolactam that is not consumed internally to customers who use it to manufacture polymer resins to produce fibers, compounds and other nylon products. Our Hopewell, VA manufacturing facility is one of the world's largest single-site producers of caprolactam as of September 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;**• Plant Nutrients –** Our ammonium sulfate is used by customers as a fertilizer containing nitrogen and sulfur, two key plant nutrients. Ammonium sulfate fertilizer is derived from the integrated operations at the Hopewell manufacturing facility. Because of our Hopewell facility's size, scale and technology design, we are the world's largest single-site producer of ammonium sulfate fertilizer as of September 30, 2025. We market and sell ammonium sulfate primarily to North American and South American distributors, farm cooperatives and retailers to fertilize crops. We also manufacture sulfuric acid, ammonia and carbon dioxide as part of our integrated operations at Hopewell and occasionally sell any excess material not consumed internally to customers externally.

&nbsp;&nbsp;&nbsp;&nbsp;**• Chemical Intermediates –** We manufacture, market and sell a number of chemical intermediate products that are derived from the manufacturing processes within our integrated supply chain. Most significant is acetone which is used by our customers in the production of solvents, paints, coatings, adhesives, resins and herbicides. Other intermediate chemicals that we manufacture, market and sell include phenol, alpha-methylstyrene, cyclohexanone, oximes, cyclohexanol, and alkyl and specialty amines. Additional end-products for intermediates include automotive components, and water treatment and pharmaceutical intermediates.

Global demand for Nylon 6 resin spans a variety of end-uses such as textiles, engineered plastics, industrial filament, food and industrial films, and carpet. The market growth typically tracks global GDP growth over the long-term but varies by end-use. We produce and sell caprolactam as a commodity product and produce and sell our Nylon 6 resin as both a commoditized and differentiated resin product. Our results of operations are primarily driven by production volume and the spread between the sales prices of our products and the costs of the underlying raw materials built into market-based and value-based pricing models. The global prices for nylon resin typically track a spread over the price of caprolactam, which in turn tracks as a spread over benzene because the key feedstock materials for caprolactam, phenol or cyclohexane, are derived from benzene. This price spread has historically experienced cyclicality as a result of global changes in supply and demand. Generally, Nylon 6 resin prices track the cyclicality of caprolactam prices, although prices set above the spread are achievable when nylon resin manufacturers, like AdvanSix, formulate and produce differentiated nylon resin products for current and new customer applications, such as our wire and cable and co-polymer offerings.

Global prices for ammonium sulfate fertilizer are influenced by several factors including the price of urea, which is the most widely used source of nitrogen-based fertilizer in the world. Other global factors driving ammonium sulfate fertilizer demand are general agriculture trends, including planted acres and the price of crops. Our ammonium sulfate product is positioned with the added value proposition of sulfur nutrition to increase yields of key crops. In addition, due to its nutrient density, the typical ammonium sulfate product delivers pound for pound the most readily available sulfur and nitrogen to crops as compared to other fertilizers. We also directly supply packaged ammonium sulfate to customers, primarily in North and South America, and have diversified and optimized our offerings to include spray-grade adjuvants to support crop protection, as well as other specialty fertilizers and products for industrial use.

Our ammonium sulfate fertilizer experiences quarterly sales seasonality reflecting both geographical and product sales mix considerations based on the timing and length of the growing seasons in North and South America. The North American fertilizer season typically runs from July, when the value chain begins restocking fertilizer, through June of the following year, when most application for the year's planting is completed. The new season fill begins in the third quarter and proceeds sequentially into the following spring, which is the peak period for crop fertilizer application. As a result of this pattern, North American ammonium sulfate demand and pricing, particularly for our higher-value granular product, are typically strongest in

------

the first half of the year through application for the spring crop and then decline in the second half of the year. Ammonium sulfate industry prices in the corn belt have declined approximately 12% from the second quarter to the third quarter, on average, since 2016. Due to the ammonium sulfate fertilizer sales cycle, we occasionally build up higher inventory balances because our production is continuous throughout the year and not tied to seasonal demand for fertilizers. Sales of most of our other products have generally been subject to minimal, or no, seasonality.

We also manufacture, market and sell a number of chemical intermediate products that are derived from the manufacturing processes within our integrated supply chain. Most significant is acetone, the price of which is influenced by its own supply and demand dynamics but can also be influenced by the underlying move in propylene input costs. Our differentiated product offerings include high-purity applications and high-value intermediates including our U.S. Amines portfolio as well as our oximes-based EZ-Blox™ anti-skinning agent used in paints and Nadone® cyclohexanone, which is a solvent used in various high-value applications.

We seek to run our production facilities on a nearly continuous basis for maximum efficiency as several of our intermediate products are key feedstock materials for other products in our integrated manufacturing chain. While our integration, scale and range of product offerings make us one of the most efficient manufacturers in our industry, these attributes also expose us to increased risk associated with material disruptions at any one of our production facilities or logistics operations which could impact the overall manufacturing supply chain. Further, although we believe that our sources of supply for our raw materials, including cumene, natural gas and sulfur, are generally robust, it is difficult to predict the impact that shortages, increased costs and related supply chain logistics considerations may have in the future. In order to mitigate the risk of unplanned interruptions, we schedule planned plant turnarounds each year to conduct routine and major maintenance across our facilities. We also utilize maintenance excellence and mechanical integrity programs, targeted buffer inventory of intermediate chemicals necessary for our manufacturing process, and co-producer swap arrangements, which are intended to mitigate the extent of any production losses as a result of planned and unplanned downtime; however, the mitigation of all or part of any such production impact cannot be assured.

**Recent Developments**

*<u>Amendment to Credit Agreement</u>*

On October 23, 2025, the Company entered into Amendment No. 2 (the "Amendment") to the Credit Agreement (as defined below). See "Liquidity and Capital Resources - Credit Agreement" for a discussion regarding the Amendment.

*<u>Anti-Dumping Duty Petition - Acetone</u>*

On November 4, 2024, the U.S. Department of Commerce ("Commerce") initiated the first five-year review of the anti-dumping orders on imports of acetone from Belgium, Singapore, South Africa, South Korea, and Spain. On November 1, 2024, the U.S. International Trade Commission ("ITC") issued its notice of initiation of its five-year review of the orders. The anti-dumping orders and applicable duties will continue for another five-year period if Commerce finds that revocation of the orders is likely to lead to continuation or recurrence of dumping and if the ITC finds that revocation is likely to lead to continuation or recurrence of material injury to the U.S. domestic industry. On December 26, 2024, Commerce notified the ITC that it would conduct an expedited review and issue its results no later than March 4, 2025. On February 4, 2025, the ITC voted to conduct a full review and is expected to issue its results in the fourth quarter of 2025. On March 7, 2025, Commerce determined that revocation of the anti-dumping orders would likely lead to continuation of recurrence of dumping. The anti-dumping duties will continue to apply during the ITC's pending review.

*<u>Philadelphia Energy Solutions' Shut Down</u>*

The Company previously reported a business impact associated with the June 2019 fire that shut down the Philadelphia Energy Solutions ("PES") refinery in Philadelphia, Pennsylvania. PES was one of multiple suppliers to the Company of cumene, a feedstock material used to produce phenol, acetone and other chemical intermediates. The Company has been actively pursuing the claim over several years, with a final omnibus settlement in January 2025 which resulted in insurance settlement proceeds of approximately $26 million in the first quarter of 2025. The total aggregate insurance proceeds since the original claim submission are approximately $39 million.

**<u>Results of Operations</u>**

(Dollars in thousands, unless otherwise noted)

**Sales**

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2025** | **2024** | **2025** | **2025** | **2024** |
| Sales | $| 374473 | $398187 | $| 1162286 | $1188495 |
| % change compared with prior year period | (6.0)% | (6.0)% |  | (2.2)% | (2.2)% |  |

---

The change in sales compared to the prior year period is attributable to the following:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>September 30, 2025** | **Nine Months Ended<br>September 30, 2025** |
| Volume | (3.2)% | (1.9)% |
| Price | (2.8)% | (0.3)% |
|  | (6.0)% | (2.2)% |

---

Sales decreased in the three months ended September 30, 2025 compared to the prior year period by $23.7 million (approximately 6%) due to (i) lower raw material pass through pricing (approximately 5%) following a net cost decrease in benzene and propylene (inputs to cumene which is a key feedstock to our products) and (ii) decreased volume (approximately 3%) primarily driven by softer demand in chemical intermediate and nylon end markets, partially offset by favorable market-based pricing (approximately 2%) driven by continued strength in Plant Nutrients reflecting favorable North American ammonium sulfate supply and demand conditions.

Sales decreased in the nine months ended September 30, 2025 compared to the prior year period by $26.2 million (approximately 2%) due to decreased volume (approximately 2%) driven by softer demand in nylon end markets partially offset by higher granular ammonium sulfate sales supported by our SUSTAIN (Sustainable U.S. Sulfate to Accelerate Increased Nutrition) program. Pricing was flat, primarily reflecting favorable market-based pricing across our Plant Nutrients and Nylon Solutions product lines offset by lower raw material pass through pricing following a net cost decrease in benzene and propylene.

**Costs of Goods Sold**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| Costs of goods sold | $| 349088 | $| 340885 | $| 1024716 | $| 1046860 |
| % change compared with prior year period | 2.4% | 2.4% |  |  | (2.1)% | (2.1)% |  |  |
| Gross Margin percentage | 6.8% | 6.8% | 14.4% | 14.4% | 11.8% | 11.8% | 11.9% | 11.9% |

---

Costs of goods sold increased in the three months ended September 30, 2025 compared to the prior year period by $8.2 million (approximately 2%) due to (i) increased plant costs (approximately 2%) driven primarily by utility costs and (ii) increased raw material costs (approximately 1%) driven by sulfur and natural gas.

Costs of goods sold decreased in the nine months ended September 30, 2025 compared to the prior year period by $22.1 million (approximately 2%) due to (i) insurance proceeds collected as a result of the PES supplier shutdown (approximately 3%),and (ii) decreased sales volume (approximately 3%), partially offset by (i) increased raw material costs (approximately 2%) driven by sulfur and natural gas and (ii) increased plant costs driven primarily by utility costs (approximately 1%).

Gross margin percentage decreased in the three months ended September 30, 2025 compared to the prior year period (approximately 8%) due primarily to (i) the impact of pricing, net of raw material costs (approximately 3%), (ii) increased plant costs driven primarily by utility costs (approximately 2%), and (iii) lower sales volumes as discussed above (approximately 2%).

Gross margin percentage was approximately flat in the nine months ended September 30, 2025 compared to the prior year period due to insurance proceeds collected as a result of the PES supplier shutdown (approximately 2%), offset by the impact of pricing, net of raw material costs (approximately 2%).

**Selling, General and Administrative Expenses**

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| Selling, general and administrative expenses | $| 27425 | $| 24265 | $| 76250 | $| 72290 |
| Percentage of Sales | 7.3% | 7.3% | 6.1% | 6.1% | 6.6% | 6.6% | 6.1% | 6.1% |

---

Selling, general and administrative expenses increased by $3.2 million in the three months ended September 30, 2025 compared to the prior year period due primarily to legal and professional fees associated with strategic regulatory matters and potential inorganic growth options, and the planned investment to upgrade our enterprise resource planning system.

Selling, general and administrative expenses increased by $4.0 million in the nine months ended September 30, 2025 compared to the prior period due primarily to legal and professional fees associated with strategic regulatory matters and potential inorganic growth options, and the planned investment to upgrade our enterprise resource planning system.

**Income Tax Expense (Benefit)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| Income tax expense (benefit) | $| (909) | $| 7479 | $| 4955 | $| 14603 |
| Effective tax rate | 25.6% | 25.6% | 25.1% | 25.1% | 8.7% | 8.7% | 25.0% | 25.0% |

---

The Company's provision (benefit) for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income (loss) before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The Company's effective tax rate for the three and nine months ended September 30, 2025 and 2024 differed from the U.S. federal statutory rate due to state taxes and executive compensation deduction limitations which generally increase the rate, offset by research tax credits and the foreign-derived intangible income deduction that generally decrease the rate. During the nine months ended September 30, 2025, discrete tax adjustments recorded relating to Internal Revenue Code (IRC) Section 45Q tax credits of $9.7 million and return to provision adjustments related to the filing of the Company's 2024 U.S. federal income tax return of $0.2 million, offset slightly by state tax legislation changes and the vesting of equity compensation, resulted in a net 5% increase and 17% decrease in the estimated annual effective tax rate for the three and nine months ended September 30, 2025, respectively. In 2024, the Company recorded discrete tax adjustments related to the vesting of equity compensation, changes to state tax legislation, and return to provision adjustments related to the filing of the Company's 2023 U.S. federal income tax return which resulted in a net 3.3% and 1.5% increase to the estimated annual effective tax rate for the three and nine months ended September 30, 2024, respectively.

The Company's effective tax rate for the three months ended September 30, 2025 was marginally higher than the prior year period. The increase was mainly attributed to the effect of return-to-provision adjustments on the tax rate during the three months ended September 30, 2025, relative to the prior year period, partially offset by a reduction in state taxes during the three months ended September 30, 2025 relative to the prior year period.

The Company's effective tax rate for the nine months ended September 30, 2025 was lower than the prior year period due primarily to the impact of the IRC Section 45Q tax credits recorded in the current year-to-date period compared to the prior year-to-date period.

On July 4, 2025, President Trump signed into law legislation commonly referred to as the One Big Beautiful Bill Act (the "Act"), which includes numerous tax provisions affecting businesses, including the reinstatement of full expensing of domestic research and experimental expenditures, modification of the limitation on business interest and making permanent full expensing for certain business property. These provisions resulted in an approximate $10 million reduction in cash taxes in our financial results for the three and nine months ended September 30, 2025 and we anticipate that it will also reduce our cash taxes in future periods. However, due to the elective applicability of these provisions, we are still evaluating the full impact and timing that these provisions will have on our financial results. We do not currently anticipate that the Act will have a material impact on our effective tax rate.

**Net Income**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income (loss) | $(2638) | $22266 | $52077 | $43797 |

---

As a result of the factors described above, Net income (loss) was ($2.6) million and $52.1 million for the three and nine months ended September 30, 2025, respectively, as compared to $22.3 million and $43.8 million in the corresponding prior year period.

**<u>Non-GAAP Measures</u>**

(Dollars in thousands, unless otherwise noted)

The following tables set forth the non-GAAP financial measures of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net income and Adjusted EPS. Adjusted EBITDA is defined as Net income before Interest, Income taxes, Depreciation and amortization, Non-cash stock-based compensation, Non-recurring, unusual or extraordinary expenses, Non-cash amortization from acquisitions and One-time merger and acquisition costs. Adjusted EBITDA Margin is equal to Adjusted EBITDA divided by Sales. The Company believes these non-GAAP financial measures provide meaningful supplemental information as they are used by the Company's management to evaluate the Company's operating performance, enhance a reader's understanding of the financial performance of the Company, and facilitate a better comparison among fiscal periods and performance relative to its competitors, as the non-GAAP measures exclude items that management believes do not reflect the Company's ongoing operations.

These non-GAAP results are presented for supplemental informational purposes only and should not be considered a substitute for the financial information presented in accordance with U.S. GAAP. Non-GAAP financial measures should be read only in conjunction with the comparable U.S. GAAP financial measures. The Company's non-GAAP measures may not be comparable to other companies' non-GAAP measures.

The following is a reconciliation between the non-GAAP financial measures of Adjusted Net income, Adjusted EBITDA and Adjusted EBITDA Margin to their most directly comparable U.S. GAAP financial measure:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2024** | **2025** | **2024** |
| Net income (loss) | (2638) | $| 22266 | 52077 | 43797 |
| Non-cash stock-based compensation | 1632 | 1559 | 1559 | 5919 | 5963 |
| Non-recurring, unusual or extraordinary expense\* |  |  |  |  | 1200 |
| Non-cash amortization from acquisitions | 532 | 531 | 531 | 1595 | 1595 |
| Strategic advisory and professional fees\*\* | 4000 |  |  | 4000 |  |
| Income tax benefit relating to reconciling items | (1378) | (367) | (367) | (2287) | (1594) |
| Adjusted Net income (non-GAAP) | 2148 | 23989 | 23989 | 61304 | 50961 |
| Interest expense, net | 2322 | 2924 | 2924 | 6119 | 9137 |
| Income tax expense - Adjusted | 469 | 7846 | 7846 | 7242 | 16197 |
| Depreciation and amortization - Adjusted | 19795 | 18402 | 18402 | 57371 | 55602 |
| Adjusted EBITDA (non-GAAP) | 24734 | $| 53161 | 132036 | 131897 |
| Sales | 374473 | $| 398187 | 1162286 | 1188495 |
| Adjusted EBITDA Margin\*\*\* (non-GAAP) | 6.6% | 13.4% | 13.4% | 11.4% | 11.1% |

---

*\* 2024 includes a pre-tax loss of approximately $1.2 million from the reduction of the Company's anticipated receivable related to the gain on the termination fee recorded upon the exit from the Oben Holding Group S.A. alliance during the third quarter of 2023.*

*\*\* Legal and professional fees associated with strategic regulatory matters and potential inorganic growth options.*

*\*\*\* Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Sales.*

The following is a reconciliation between the non-GAAP financial measures of Adjusted EPS to its most directly comparable U.S. GAAP financial measure:

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>September 30,** | **Three Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income (loss) | $(2638) | $22266 | $52077 | $43797 |
| Adjusted Net income (non-GAAP) | 2148 | 23989 | 61304 | 50961 |
| Weighted-average number of common shares outstanding - basic | 26927305 | 26790752 | 26887489 | 26836114 |
| Dilutive effect of equity awards and other stock-based holdings |  | 413962 | 361270 | 373566 |
| Weighted-average number of common shares outstanding - diluted | 26927305 | 27204714 | 27248759 | 27209680 |
| EPS - Basic | $(0.10) | $0.83 | $1.94 | $1.63 |
| EPS - Diluted | $(0.10) | $0.82 | $1.91 | $1.61 |
| Adjusted EPS - Basic (non-GAAP) | $0.08 | $0.90 | $2.28 | $1.90 |
| Adjusted EPS - Diluted (non-GAAP) | $0.08 | $0.88 | $2.25 | $1.87 |

---

**<u>Liquidity and Capital Resources</u>**

(Dollars in thousands, unless otherwise noted)

**Liquidity**

We believe that cash balances and operating cash flows, together with available capacity under our credit agreement, as utilized in the third quarter of 2025, will provide adequate funds to support our current short-term operating objectives as well as our longer-term strategic plans, subject to the risks and uncertainties outlined below, in our "Note Regarding Forward-Looking Statements" above, and in the risk factors previously disclosed in Item 1A of Part I of our 2024 Form 10-K. Our principal source of liquidity is our cash flow generated from operating activities, which is expected to provide us with the ability to meet the majority of our short-term funding requirements for the next twelve months and beyond. Our cash flows are affected by capital requirements and production volume, which may be materially impacted by unanticipated events such as unplanned downtime, material disruptions at our production facilities, the prices of our raw materials, general economic and industry trends and customer demand. The Company applies a proactive and disciplined approach to working capital management to optimize cash flow and to enable capital allocation options in support of the Company's strategy. We utilize supply chain financing and trade receivables discount arrangements with third-party financial institutions which optimize terms and conditions related to accounts receivable and accounts payable in order to enhance liquidity and enable us to efficiently manage our working capital needs. Although we continue to optimize supply chain financing and trade receivable programs in the ordinary course, our utilization of these arrangements has not had a material impact on our liquidity. In addition, we monitor the third-party depository institutions that hold our cash and cash equivalents. Our emphasis is primarily on the safety of principal and secondarily on maximizing yield on those funds. We diversify our cash and cash equivalents among counterparties to minimize exposure to any one of these entities.

On a recurring basis, our primary future cash needs will be centered on operating activities, working capital, capital expenditures, dividends and liquidity reflecting disciplined capital deployment. Capital expenditures are deployed for various ongoing investments and initiatives to improve reliability, yield and quality, expand production capacity and comply with health, safety and environmental ("HSE") regulations. We believe that our future cash from operations, cash on hand and available capacity under our credit agreement, as well as our access to credit and capital markets, will provide adequate resources to fund our expected operating and financing needs and obligations. Our ability to fund our capital needs, however, will depend on our ongoing ability to generate cash from operations and access to credit and capital markets, both of which are subject to the risk factors previously disclosed in Item 1A of Part I of our 2024 Form 10-K, as well as general economic, financial, competitive, regulatory and other factors that are beyond our control.

As of the end of the third quarter of 2025, the Company had approximately $23.7 million of cash on hand with approximately $249 million of additional capacity available under the revolving credit facility. The Company's Consolidated Leverage Ratio financial covenant of its credit facility allows it to net up to $75 million of cash with debt. Capital expenditures are expected to

------

be approximately $120 million to $125 million in 2025 compared to $134 million in 2024, reflecting the planned progression of our SUSTAIN growth program, and refined execution timing to address critical enterprise risk mitigation.

We assumed from Honeywell International Inc. ("Honeywell") all HSE liabilities and compliance obligations related to the past and future operations of our current business as of the spin-off, as well as all HSE liabilities associated with the three manufacturing locations assumed from Honeywell that are used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to have a material adverse effect on the Company's consolidated financial position or results of operations.

We expect that our primary cash requirements for 2025 will be to fund costs associated with ongoing operations, capital expenditures, and amounts related to other contractual obligations.

The Company made no cash contributions to the defined benefit pension plan during the nine months ended September 30, 2025 as there were no funding requirements for the period. Additional contributions may be made in future periods sufficient to satisfy pension funding requirements in those periods or on a discretionary basis.

As of September 30, 2025, the Company has repurchased a total of 6,313,789 shares of common stock life-to-date, including 1,068,333 shares withheld to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $194.1 million at a weighted average market price of $30.74 per share. As of September 30, 2025, approximately $62.0 million remained available for share repurchases under the current authorization approved by the Board on February 17, 2023. During the period October 1, 2025 through October 31, 2025, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Exchange Act, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.

As of September 30, 2025, the Company did not have any off-balance sheet arrangements as described in Instruction 8 to Item 303(b) of Regulation S-K and did not have any material changes in the commitments or contractual obligations detailed in the 2024 Form 10-K (see Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" under "Liquidity and Capital Resources - Liquidity"). The Company has not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.

*<u>Dividends</u>*

The Company commenced the declaration of dividends on September 28, 2021.

Dividends paid during 2025 and the dividend announced on the date of this filing are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Date of Announcement** | **Date of Record** | **Date Payable** | **Dividend per Share** | **Total Approximate Dividend Amount ($M)** |
| 11/7/2025 | 11/18/2025 | 12/2/2025 | $0.16 | $4.3 |
| 8/1/2025 | 8/12/2025 | 8/26/2025 | $0.16 | $4.3 |
| 5/2/2025 | 5/13/2025 | 5/27/2025 | $0.16 | $4.3 |
| 2/21/2025 | 3/10/2025 | 3/24/2025 | $0.16 | $4.3 |

---

The timing, declaration, amount and payment of future dividends to stockholders, if any, will fall within the discretion of our Board. Holders of shares of our common stock will be entitled to receive dividends when, and if, declared by our Board at its discretion out of funds legally available for that purpose, subject to the terms of our indebtedness, the preferential rights of any preferred stock that may be outstanding, legal requirements, regulatory constraints, industry practice and other factors that our Board deems relevant.

------

**Credit Agreement**

On October 27, 2021, the Company entered into a Credit Agreement, as amended on June 27, 2023 (the "Credit Agreement"), among the Company, the lenders party thereto, the swing line lenders party thereto, the letter of credit issuers party thereto and Truist Bank, as administrative agent, which provides for a senior secured revolving credit facility in an aggregate principal amount of $500 million (the "Revolving Credit Facility").

Borrowings under the Revolving Credit Facility are subject to customary borrowing conditions.

The Revolving Credit Facility provided for a scheduled maturity date of October 27, 2026. The Credit Agreement permits the Company to utilize up to $40 million of the Revolving Credit Facility for the issuance of letters of credit and up to $40 million for swing line loans. The Company has the option to establish a new class of term loans and/or increase the amount of the Revolving Credit Facility in an aggregate principal amount for all such incremental term loans and increases of the Revolving Credit Facility of up to the sum of (x) $175 million plus (y) an amount such that the Company's Consolidated First Lien Secured Leverage Ratio (as defined in the Credit Agreement) would not be greater than 2.75 to 1.00, in each case, to the extent that any one or more lenders, whether or not currently party to the Credit Agreement, commits to be a lender for such amount or any portion thereof.

Borrowings under the Credit Agreement bear interest at a rate equal to either the sum of a base rate plus a margin ranging from 0.25% to 1.25% or the sum of an Adjusted Term SOFR rate plus a margin ranging from 1.25% to 2.25%, with either such margin varying according to the Company's Consolidated Leverage Ratio (as defined in the Credit Agreement). The Company is also required to pay a commitment fee in respect of unused commitments under the Revolving Credit Facility, if any, at a rate ranging from 0.15% to 0.35% per annum depending on the Company's Consolidated Leverage Ratio.

Substantially all tangible and intangible assets of the Company and its domestic subsidiaries are pledged as collateral to secure the Company's obligations under the Credit Agreement.

The Credit Agreement contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, pay cash dividends, incur debt or liens, redeem or repurchase stock of the Company, enter into transactions with affiliates, make investments, make capital expenditures, merge or consolidate with others or dispose of assets. The Credit Agreement also contains financial covenants that require the Company to maintain a Consolidated Interest Coverage Ratio (as defined in the Credit Agreement) of not less than 3.00 to 1.00 and to maintain a Consolidated Leverage Ratio of (ii) 3.75 to 1.00 or less (subject to the Company's option to elect a consolidated leverage ratio increase in connection with certain acquisitions). If the Company does not comply with the covenants in the Credit Agreement, the lenders may, subject to customary cure rights, require the immediate payment of all amounts outstanding under the Revolving Credit Facility. We were in compliance with all of our covenants at September 30, 2025 and through the date of the filing of this Form 10-Q.

We had a borrowed balance of $195 million under the Revolving Credit Facility at December 31, 2024. We borrowed an incremental net amount of $55 million during the nine months ended September 30, 2025, bringing the balance under the Revolving Credit Facility to $250 million, and available credit for use of approximately $249 million as of September 30, 2025. We expect that Cash provided by operating activities will fund future interest payments on the Company's outstanding indebtedness.

On October 23, 2025, the Company entered into Amendment No. 2 (the "Amendment") to the Credit Agreement, (as further amended by the Amendment, the "Amended Credit Agreement"), among the Company, the guarantors, the lenders party thereto and Truist Bank, as administrative agent.

The Credit Agreement includes a senior secured revolving credit facility with aggregate commitments of $500 million (the "Revolving Credit Commitments"). Pursuant to the Amendment, the Credit Agreement was amended to, among other things: (i) extend the maturity date of revolving credit commitments of participating Revolving Credit Lenders, as defined in the Amended Credit Agreement, in an aggregate principal amount of $452 million to the earlier of (x) October 27, 2027 and (y) the date of the termination in whole of the Revolving Credit Commitments, pursuant to the terms of the Amended Credit Agreement, and (ii) effect certain other conforming changes and modifications consistent with the foregoing. The remaining $48 million of revolving credit commitments under the Credit Agreement that were not extended will continue to mature on the earlier of (x) October 27, 2026 and (y) the date of the termination in whole of the Revolving Credit Commitments, pursuant to the terms of the Amended Credit Agreement.

**Cash Flow Summary**

------

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>September 30,** | **Nine Months Ended<br>September 30,** |
| | **2025** | **2024** |
| Cash provided by (used for): |  |  |
| &nbsp;&nbsp;Operating activities | $59141 | $71248 |
| &nbsp;&nbsp;Investing activities | (95002) | (105426) |
| &nbsp;&nbsp;Financing activities | 39993 | 21708 |
| Net change in cash and cash equivalents | $4132 | $(12470) |

---

Cash provided by operating activities decreased by $12.1 million for the nine months ended September 30, 2025 versus the prior year period due primarily to (i) the unfavorable cash impact of $17.7 million from Taxes receivable and Income taxes payable combined, driven by the timing of tax receipts and (ii) a $11.6 million unfavorable cash impact from working capital (comprised of Accounts and other receivables, Inventories, Accounts payable and Deferred income and customer advances) with $56.0 million unfavorable cash impact from working capital for the nine months ended September 30, 2025 compared to a $44.4 million unfavorable cash impact in the prior year period. These net unfavorable impacts were partially offset by (i) a favorable impact of $10.8 million from Deferred income taxes and (ii) an $8.3 million increase in Net income.

Cash used for investing activities decreased by $10.4 million for the nine months ended September 30, 2025 versus the prior year period due primarily to the timing of cash payments for capital expenditures and other enterprise programs.

Cash provided by financing activities increased by $18.3 million for the nine months ended September 30, 2025 versus the prior year period due primarily to (i) net borrowings of $55.0 million during the nine months ended September 30, 2025 compared to net borrowings of $45.0 million during the prior year period and (ii) payments for share repurchases of $1.7 million during the nine months ended September 30, 2025 compared to $10.4 million during the prior year period.

**<u>Capital Expenditures</u>**

(Dollars in thousands, unless otherwise noted)

Our operations are capital intensive, requiring ongoing investments that have consisted, and are expected to continue to consist, primarily of capital expenditures required to maintain and improve equipment reliability, expand production output, further improve mix, yield and cost position, and comply with environmental and safety regulations.

The following table summarizes ongoing and expansion capital expenditures:

---

| | |
|:---|:---|
| | **Nine Months Ended<br>September 30, 2025** |
| Capital expenditures in Accounts payable at December 31, 2024 | $23645 |
| Purchases of property, plant and equipment | 80098 |
| Less: Capital expenditures in Accounts payable at September 30, 2025 | (14894) |
| Cash paid for capital expenditures | $88849 |

---

For 2025, we expect our total capital expenditures to be approximately $120 million to $125 million as discussed above.

**<u>Critical Accounting Policies and Estimates</u>**

The preparation of our Condensed Consolidated Financial Statements in accordance with U.S. GAAP is based on the selection and application of accounting policies that require us to make significant estimates and assumptions about the effects of matters that are inherently uncertain. We consider these accounting policies to be critical to the understanding of our Condensed Consolidated Financial Statements. For a full description of our critical accounting policies, refer to Management's Discussion and Analysis of Financial Condition and Results of Operations contained in our 2024 Form 10-K. While there have been no material changes to our critical accounting policies, or the methodologies or assumptions we apply under them since the filing of the 2024 Form 10-K, we continue to monitor such methodologies and assumptions.

**<u>Recent Accounting Pronouncements</u>**

------

See "Note 2. Recent Accounting Pronouncements" to the Condensed Consolidated Financial Statements included in Part I. Item 1 of this Form 10-Q.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

**Interest Rate Risk**

Our exposure to risk based on changes in interest rates during the nine-month period ended September 30, 2025 relates primarily to the Revolving Credit Facility. The Revolving Credit Facility bears interest at floating rates. For variable rate debt, interest rate changes generally do not affect the fair market value of such debt assuming all other factors remain constant but do impact future earnings and cash flows. Accordingly, we may be exposed to interest rate risk on borrowings under the Credit Agreement.

Based on current borrowing levels at September 30, 2025, a 25-basis point fluctuation in interest rates for the nine months ended September 30, 2025 would have resulted in an increase or decrease to our interest expense of approximately $0.6 million.

See "Note 2. Summary of Significant Accounting Policies" to the Consolidated Financial Statements included in Item 8 of our 2024 Form 10-K for a discussion relating to credit and market, commodity price and interest rate risk management.

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

The Company maintains disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to management, including the Chief Executive Officer and Interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud have been, or will be, detected.

Our Chief Executive Officer and Interim Chief Financial Officer, with the assistance of other members of our management, conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based upon such evaluation, our Chief Executive Officer and Interim Chief Financial Officer have concluded that our disclosure controls and procedures are effective at a reasonable assurance level as of September 30, 2025, the end of the period covered by this quarterly report.

**Changes in Internal Control over Financial Reporting**

Management has not identified any change in the Company's internal control over financial reporting that occurred during the quarter ended September 30, 2025 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

During the current period, the Company implemented the new enterprise resource planning ("ERP") system which replaced existing operating and financial systems. The new ERP system is designed to provide enhanced transactional processing, reporting, security and management tools. The Company evaluated its control processes and determined that no significant modifications were needed to maintain the effectiveness of its internal controls over financial reporting. The Company will continue to monitor and evaluate its control processes to determine whether any modifications are needed to maintain the effectiveness of its internal controls over financial reporting.

**PART II. OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

------

As previously reported, the Virginia Department of Environmental Quality ("VA DEQ") initiated discussions with the Company regarding certain alleged violations associated with air emissions and water discharges at the Company's Hopewell facility. The Company entered into an Order by Consent with the VA DEQ in September 2025 in connection with the alleged water discharge violations of the State Water Control Law at the Company's facility in Hopewell, Virginia, which provided for a civil charge of $55,841. The facility is continuing to assess and discuss the allegations associated with air emissions with the VA DEQ. Although the outcome of the matter cannot be predicted with certainty, we do not believe that it will have a material adverse effect on our consolidated financial position, results of operations or operating cash flows.

From time to time, we are involved in litigation relating to claims arising outside of the ordinary course of our business operations. We are not a party to, and, to our knowledge, there are no pending claims or actions against us, the ultimate disposition of which could be expected to have a material adverse effect on our consolidated financial position, results of operations or operating cash flows.

**ITEM 1A. RISK FACTORS**

There have been no material changes to our risk factors as previously disclosed in Item 1A of Part I of the 2024 Form 10-K, which are hereby incorporated by reference.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

On May 4, 2018, the Company announced that the Board authorized a share repurchase program of up to $75 million of the Company's common stock. On February 22, 2019, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity authorized under the May 2018 share repurchase program. On February 17, 2023, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity available under the previously approved share repurchase program. Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Exchange Act, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The repurchase program has no expiration date and may be modified, suspended or discontinued at any time.

The below table sets forth the repurchases of Company common stock, by month, for the quarter ended September 30, 2025. During the quarter ended September 30, 2025, no additional shares were purchased under our share repurchase program and 5,690 shares were withheld to cover tax withholding obligations in connection with the vesting of equity awards.

**ISSUER PURCHASES OF EQUITY SECURITIES**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Period** | | **Total Number of Shares Purchased** | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Plan** | **Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan** |
| July 2025 |  |  | $— |  | $61957898 |
| August 2025 |  |  |  |  | 61957898 |
| September 2025 | (1) | 5690 | 21.34 |  | 61957898 |
| Total |  | 5690 | $21.34 |  |  |

---

(1) Total number of shares purchased includes 5,690 shares covering tax withholding obligations in connection with the vesting of equity awards

During the period October 1, 2025 through October 31, 2025, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

**ITEM 5. OTHER INFORMATION**

**Insider Rule 10b5-1 Trading Plans**

During the quarter ended September 30, 2025, none of our directors or executive officers adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" as those terms are defined in Item 408 of Regulation S-K.

------

**ITEM 6. EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 3.1 | <u>[Amended and Restated Certificate of Incorporation of AdvanSix Inc. (conformed copy)](https://www.sec.gov/Archives/edgar/data/1673985/000167398525000119/exhibit31_conformedarcerti.htm)[(incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q](https://www.sec.gov/Archives/edgar/data/1673985/000167398525000119/exhibit31_conformedarcerti.htm)[filed on August 1, 2025)](https://www.sec.gov/Archives/edgar/data/1673985/000167398525000119/exhibit31_conformedarcerti.htm)</u> |
| 3.2 | <u>[Amended and Restated By-laws of AdvanSix Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 20, 2023).](https://www.sec.gov/Archives/edgar/data/1673985/000167398523000091/exhibit31amendedandrestate.htm)</u> |
| 10.1 | <u>[Employment Separation Agreement and Release between AdvanSix Inc. and Siddharth Manjeshwar, dated July 9, 2025](exhibit101_manjeshwarsepar.htm)[†](exhibit101_manjeshwarsepar.htm)</u> |
| 10.2 | <u>[Amendment No. 2 to Credit Agreement, dated as of October 23, 2025, among AdvanSix Inc., the guarantors, the lenders signatory thereto and Truist Bank, as the administrative agent (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on October 23, 2025)](https://www.sec.gov/Archives/edgar/data/1673985/000095015725000887/ex10-1.htm)</u> |
| 31.1 | <u>[Rule 13a-14(a)/15d-14(a) Certification of the Company's Principal Executive Officer.](a10q2025exhibit311ceo.htm)</u> |
| 31.2 | <u>[Rule 13a-14(a)/15d-14(a) Certification of the Company's Principal Financial Officer.](a10q2025exhibit312cfo.htm)</u> |
| 32.1 | <u>[Section 1350 Certification of the Company's Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.](a10q2025exhibit321ceosox.htm)</u> |
| 32.2 | <u>[Section 1350 Certification of the Company's Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.](a10q2025exhibit322cfosox.htm)</u> |
| 101.INS | Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101) |

---

† Indicates management contract or compensatory plan.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | ADVANSIX INC. | ADVANSIX INC. |
| Date: November 7, 2025 | By: | /s/ Christopher Gramm |
|  |  | **Christopher Gramm** |
|  |  | **Vice President and Interim Chief Financial Officer** |

---

## Exhibit 10.1

Exhibit 10.1

July 9, 2025

Siddharth Manjeshwar

AdvanSix Inc.

300 Kimball Drive, Suite 101

Parsippany, NJ 07054

Re: Employment Separation Agreement and Release

Mr. Manjeshwar,

This Employment Separation Agreement and Release ("<u>Agreement</u>") confirms our mutual understanding regarding your rights and benefits incident to your termination of employment with AdvanSix Inc., its predecessor companies, affiliates, subsidiaries and business units, past and present ("<u>AdvanSix</u>" or the "<u>Company</u>"). By signing this Agreement, you hereby acknowledge and agree that the benefits outlined in this letter are in full satisfaction of all rights to termination or severance-related benefits for which you may have been eligible or may claim to be eligible under any agreement or promise, whether written or oral, express or implied, or any Company-sponsored severance plan or program, including the Executive Severance Pay Plan of AdvanSix Inc. ("<u>Executive Severance Plan</u>"), and that you are not entitled to any termination or severance-related benefits except as provided in Section 2 below.

SECTION 1. <u>Cessation of Employment Relationship</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)You will cease to serve as Senior Vice President and Chief Financial Officer, and as an officer of the Company, effective July 9, 2025 ("<u>Separation Date</u>"). Effective on the Separation Date, your employment with the Company will automatically terminate without the need for any further action by the Company, you or any other party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Effective as of the Separation Date, you hereby resign from all positions, offices and directorships with the Company.

SECTION 2. <u>Payment Obligations</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Payment for Accrued Salary, Benefits, Etc</u>. Following the Separation Date, you will be entitled to receive from the Company a cash payment equal to any accrued and unpaid compensation for your period of employment through the Separation Date and will be paid any vested and accrued but not yet paid amounts due under the terms and conditions of the Company's 401(k) Plan, and any other employee benefit plans in accordance with the terms of such plan and applicable law. You will also continue to participate in the health plans in which you currently participate through the end of the month in which the Separation Date occurs. Following the Separation Date, you may elect to continue medical, dental and vision plan coverage in accordance with the provisions of the Consolidated Omnibus Budget Reconciliation Act at your own expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Severance</u>. You and the Company agree that your separation from employment with the Company will be treated as a Covered Termination pursuant to the Executive Severance Plan, provided that your employment is not terminated by the Company for Cause (as defined in the Executive Severance Plan) prior to the Separation Date. As a result of your Covered Termination, the Company will pay you a lump sum cash payment of $591,623.29 (representing an amount equal to one (1) times the sum of your Base Salary <u>plus</u> your Prior Year Bonus (as each such term is defined in the Executive Severance Plan), <u>less</u> the payback of $25,000 (representing your sign-on cash bonus given your separation from the Company occurred within two years of your start date

------

with AdvanSix), payable within 30 days after the Separation Date, subject to Sections 3 and 5(f) below.

For the avoidance of doubt, effective as of the date of this Agreement, you are not entitled to: (i) any future Company long-term equity incentive awards; (ii) payment of any award under the AdvanSix Inc. Short-Term Incentive Plan ("STIP") for the 2025 plan year; or (iii) payment of any amounts in connection with vacation or paid time off. In accordance with the terms of the applicable award agreements, any unvested restricted stock unit awards, performance stock unit awards and stock option awards that you hold as of the Separation Date will be immediately forfeited effective as of the Separation Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3. <u>Waiver and Release</u>.

Notwithstanding any other provisions of this Agreement to the contrary, this Agreement will not become effective, and neither the Company nor you will have any rights or obligations under this Agreement, including the payments, benefits, vesting and other rights provided to you under Section 2(b) of this Agreement, unless and until the Executive General Release attached as <u>Exhibit A</u> hereto and made a part hereof (the "<u>Release</u>") becomes effective pursuant to its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 4. <u>Post-Employment Covenants</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Non-Competition, Confidentiality, Cooperation, Other Covenants</u>. You hereby acknowledge, agree to, and will satisfy in full each of your covenants, restrictions, obligations and agreements set forth in your Noncompete Agreement for Senior Executives, dated September 12, 2024 ("<u>Noncompete Agreement</u>") attached as <u>Exhibit B</u> hereto; your Employee Agreement Relating to Trade Secrets, Proprietary and Confidential Information, dated September 11, 2024 ("<u>Trade Secrets Agreement</u>") attached as <u>Exhibit C</u> hereto; the equity award agreements between you and the Company evidencing your restricted stock unit and performance stock unit awards under the 2016 Stock Incentive Plan of AdvanSix Inc. and its Affiliates, as Amended and Restated ("<u>Grant Agreements</u>"); and the Executive Severance Plan, all of which are hereby incorporated into this Agreement by reference as if fully set forth in this Agreement ("<u>Post-Separation Covenants</u>").

Notwithstanding anything in the Executive Severance Plan to the contrary and in addition to any rights that the Company may have under Section 6 thereof and the Release and other agreements contemplated in the Executive Severance Plan, the Plan Administrator (as defined in the Executive Severance Plan) reserves the right in its sole and absolute discretion to cancel all benefits thereunder in the event a Participant (as defined in the Executive Severance Plan) engages in any activity that the Plan Administrator (as defined in the Executive Severance Plan) considers detrimental to the Company's interests, as determined by the Plan Administrator, General Counsel or Chief Human Resources Officer, or their delegees. Activities that are considered detrimental to the Company's interests include, but are not limited to: (i) any effort on the part of a Participant, either directly or indirectly, to recruit or solicit employees of the Company for employment with another company without the written approval of AdvanSix; (ii) any effort on the part of the Participant, either directly or indirectly, to recruit or solicit customers of AdvanSix for any purpose contrary to the interests of the Company; (iii) the disclosure of any Company confidential or proprietary information, or the breach of any obligations under the Participant's agreements relating to intellectual property or confidential information; (iv) any intentional misconduct substantially damaging to the property or business of the Company; (v) the commission of a fraud or misappropriation of any property, proprietary information, intellectual property or trade secrets of the Company for personal gain or for the benefit of another party; (vi) knowingly making false or misleading statements about the Company or its

------

products, officers or employees to competitors or customers or potential customers of the Company, or to current or former employees of the Company; (vii) a Participant, who is a former employee of the Company, holding himself or herself out as an active employee of the Company; or (viii) breaching any terms of the Release.

During the period in which Post-Separation Covenants are in effect, you may seek written consent from the Company's CEO to assume a position with another company or entity that otherwise would be in violation of one or more of the Post-Separation Covenants, which written consent will be provided in the CEO's sole and absolute discretion.

You agree that the Post-Separation Covenants are fair and reasonable and are an essential element of the payments, rights and benefits provided to you as contemplated by this Agreement, and but for your agreement to comply with the Post-Separation Covenants, the Company would not provide such payments, rights and benefits to you. Section 4 of this Agreement shall in all respects be subject to Paragraph 9 of the Release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Confidential and Proprietary Information</u>. You acknowledge that in connection with your employment, you have had access to information of a nature not generally disclosed to the public. You agree to keep confidential and not disclose to anyone, unless legally compelled to do so, confidential and proprietary information which includes but is not limited to all Company business and strategic plans, financial details, computer programs, manuals, contracts, current and prospective client and supplier lists, and developments owned, possessed or controlled by the Company, regardless of whether possessed or developed by you in the course of your employment ("<u>Confidential and Proprietary Information</u>"). Such Confidential and Proprietary Information may or may not be designated as confidential or proprietary and may be oral, written or electronic media. "Confidential and Proprietary Information" does not include information that (a) was already publicly known at the time of disclosure to you; (b) subsequently becomes publicly known other than through disclosure by you; or (c) is generally known within the industry. You understand that Confidential and Proprietary Information is owned and will continue to be owned solely by the Company. You agree that you have not and will not disclose, directly or indirectly, in whole or in part, any Confidential and Proprietary Information except as may be required to respond to a court order, subpoena, or other legal process. In the event you receive a court order, subpoena, or notice of other legal process requiring the disclosure of any information concerning the Company, including but not limited to Confidential and Proprietary Information, to the extent permitted by law, you will give the Company notice of such process within 48 hours of receipt, in order to provide the Company with the opportunity to seek the preclusion of the disclosure of such information. You acknowledge that you have complied and will continue to comply with this commitment, both as an employee and after the end of your employment. You also acknowledge your continuing obligations under the Company's Code of Conduct.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;You hereby confirm that you are aware and have been advised that federal securities laws prohibit any person who has material non-public information about a company from purchasing or selling securities of such company or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities, and you will continue to be subject to the Company's quarterly blackout calendar and pre-clearance policy until notified otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Without limitation of its rights at law or in equity, the Company reserves the right to suspend any payments to, vesting, benefits and other rights provided for under this Agreement if the Company has a commercially reasonable belief that you are in breach of any of your Post-Separation Covenants or Section 4 of this Agreement, or you are otherwise in

------

breach of any representation, affirmation or acknowledgement made by you under this Agreement or the Release.

SECTION 5. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Modifications</u>. This Agreement may not be modified or amended except in a writing signed by you and the Company. No term or condition of this Agreement will be deemed to have been waived except in writing by the party charged with such waiver. A waiver will operate only as to the specific term or condition waived and shall not constitute a waiver for the future or act as a waiver of anything other than that specifically waived.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. This Agreement has been executed and delivered in the State of New Jersey and its validity, interpretation, performance and enforcement will be governed by the internal laws of the State of New Jersey without reference to its conflict of laws rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Arbitration</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)Any controversy, dispute or claim arising out of or relating to this Agreement or the breach of this Agreement which cannot be settled by mutual agreement of the parties hereto (other than with respect to the matters covered by Section 4 of this Agreement, for which the Company may, but shall not be required to, seek injunctive and/or other equitable relief in a judicial proceeding; in conjunction with the foregoing, you acknowledge that the damages resulting from any breach of any such matter or provision would be irreparable and agree that the Company has the right to apply to any court of competent jurisdiction for the issuance of a temporary restraining order to maintain the status quo pending the outcome of any proceeding) will be finally settled by binding arbitration in accordance with the Federal Arbitration Act (or if not applicable, the applicable state arbitration law) as follows: Any party who is aggrieved shall deliver a notice to the other party hereto setting forth the specific points in dispute. Any points remaining in dispute twenty (20) days after the giving of such notice may be submitted to arbitration in New Jersey, to the American Arbitration Association, before a single arbitrator appointed in accordance with the Employment Arbitration Rules of the American Arbitration Association, modified only as expressly provided in this Agreement. After the aforesaid twenty (20) days, either party hereto, upon ten (10) days' notice to the other, may so submit the points in dispute to arbitration. The arbitrator may enter a default decision against any party who fails to participate in the arbitration proceedings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)The decision of the arbitrator on the points in dispute will be final, unappealable and binding, and judgment on the award may be entered in any court having jurisdiction thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)Except as otherwise provided in this Agreement, the arbitrator will be authorized to apportion his or her fees and expenses and the reasonable attorneys' fees and expenses of any such party as the arbitrator deems appropriate. In the absence of any such apportionment, the fees and expenses of the arbitrator will be borne equally by each party, and each party will bear the fees and expenses of its own attorney.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)The parties hereto agree that this Section 5(c) has been included to rapidly and inexpensively resolve any disputes between them with respect to this Agreement, and that this Section 5(c) will be grounds for dismissal of any court action commenced by either party hereto with respect to this Agreement, other than court actions commenced by the Company with respect to any matter covered by

------

Section 4 of this Agreement or any post-arbitration court actions seeking to enforce an arbitration award. **In the event that any court determines that this arbitration procedure is not binding, or otherwise allows any litigation regarding a dispute, claim, or controversy covered by this Agreement to proceed, the parties hereto hereby waive any and all rights to a trial by jury in or with respect to such litigation.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)The parties will keep confidential, and will not disclose to any person, except to counsel, financial advisors or auditors for either of the parties and/or as may be required by law, the existence of the controversy hereunder, the referral of any such controversy to arbitration, or the status of resolution thereof. This Section 5(c) shall in all respects be subject to Paragraph 9 of the Release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival</u>. Notwithstanding the execution and delivery by the parties of this Agreement, all of your obligations, covenants and restrictions under your Noncompete Agreement, your Trade Secrets Agreement, your Grant Agreements, any confidentiality agreement, any non-disclosure agreement, and the Company's Code of Conduct will survive and continue in full force and effect. This Section 5(d) shall in all respects be subject to Paragraph 9 of the Release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Enforceability; Severability</u>. It is the intention of the parties that the provisions of this Agreement shall be enforced to the fullest extent permissible under applicable law. All provisions of this Agreement are intended to be severable. In the event any provision or restriction contained in this Agreement is held to be invalid or unenforceable in any respect, in whole or in part, such finding will in no way affect the validity or enforceability of any other provision of this Agreement. The parties hereto further agree that any such invalid or unenforceable provision will be deemed modified so that it will be enforced to the greatest extent permissible under law, and to the extent that any court of competent jurisdiction determines any restrictions in this Agreement to be unenforceable in any respect, such court may limit this Agreement to render it enforceable in the light of the circumstances in which it was entered into and specifically enforce this Agreement to the fullest extent permissible.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Withholding</u>. All payments and benefits payable pursuant to this Agreement will be subject to reduction by all applicable withholding, social security and other federal, state and local taxes and deductions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Code Section 409A Compliance</u>. It is intended that this Agreement and all rights hereunder comply with, or are exempt from, the provisions of Section 409A of the Internal Revenue Code of 1986, as amended, and all regulations, guidance and other interpretive authority issued thereunder ("<u>Code Section 409A</u>") and this Agreement will be construed and applied in a manner consistent with this intent. Notwithstanding any other provision in this Agreement to the contrary, to the extent that the reimbursement of any expenses or the provision of any in-kind benefits under this Agreement is subject to Code Section 409A, reimbursement of any such expense shall be made by no later than December 31 of the year following the calendar year in which such expense is incurred. Each and every payment under this Agreement shall be treated as a separate payment under Treasury Regulation Section 1.409A-2(b)(2)(iii). Notwithstanding anything herein to the contrary, in no event whatsoever shall the Company or any of its affiliates be liable for any tax, additional tax, interest or penalty that may be imposed on the Executive pursuant to Code Section 409A or for any damages for failing to comply with Code Section 409A.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. All notices or other communications hereunder shall not be binding on either party hereto unless in writing, and delivered to the other party thereto at the following address:

If to the Company:

AdvanSix Inc.

300 Kimball Drive, Suite 100

Parsippany, NJ 07054

Attn: General Counsel

If to you:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Siddharth Manjeshwar

Notices shall be deemed duly delivered upon hand delivery at the above address, or one day after deposit with a nationally recognized overnight delivery company, or three days after deposit thereof in the United States mails, postage prepaid, certified or registered mail. Any party may change its address for notice by delivery of written notice thereof in the manner provided.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment</u>. This Agreement is personal in nature to the Company and the rights and obligations of you under this Agreement will not be assigned or transferred by you. The Company may assign this Agreement to any successor to all or a portion of the business and/or assets of the Company, provided that the Company will require such successor to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Jurisdiction</u>. Subject to Section 5(c) of this Agreement, in any suit, action or proceeding seeking to enforce any provision of this Agreement, you hereby (a) irrevocably consent to the exclusive jurisdiction of any federal court located in the State of New Jersey or any of the state courts of the State of New Jersey; (b) waive, to the fullest extent permitted by applicable law, any objection which you may now or hereafter have to the laying of venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum; and (c) agree that process in any such suit, action or proceeding may be served on you anywhere in the world, whether within or without the jurisdiction of such court, and, without limiting the foregoing, irrevocably agrees that service of process on such party, in the same manner as provided for notices in Section 5(h) of this Agreement, shall be deemed effective service of process on such party in any such suit, action or proceeding. **You and Company agree to waive any right to a jury in connection with any judicial proceeding.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together will constitute one and the same document.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings in this Agreement are intended solely for convenience of reference and will be given no effect in the construction or interpretation of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u>. This Agreement (including the Release to be executed and delivered by the Executive pursuant to Section 3 above) is entered into between you and the Company as of the date hereof and constitutes the entire understanding and

------

agreement between the parties hereto and, other than as set forth in Section 5(d) of this Agreement, supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, concerning the subject matter hereof. All negotiations by the parties concerning the subject matter hereof are merged into this Agreement, and there are no representations, warranties, covenants, understandings or agreements, oral or otherwise, in relation thereto by the parties hereto other than those incorporated herein.

[SIGNATURE PAGE FOLLOWS]

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned parties have executed this Agreement as of the date first written above or as noted below.

ADVANSIX INC.

By: <u>/s/ Erin N. Kane</u>

Name: Erin N. Kane

Title: Chief Executive Officer

<u>/s/ Siddharth Manjeshwar</u>

Executive: Siddharth Manjeshwar

Date Signed: July 13, 2025

**<u>EXHIBIT A</u>**

**<u>EXECUTIVE GENERAL RELEASE</u>**

I, Siddharth Manjeshwar ("<u>I</u>" or "<u>Executive</u>"), on behalf of myself and my heirs, executors, administrators, successors and assigns, in consideration of my Employment Separation Agreement and General Release with AdvanSix Inc., a Delaware corporation (the "<u>Company</u>"), dated July 9, 2025 (the "<u>Agreement</u>"), to which this Executive General Release (this "<u>Release</u>") is attached, do hereby knowingly and voluntarily release and forever discharge the Company, its predecessor companies, and each of its and their parent entities, affiliates and subsidiaries, and each of its and their past, present and future subsidiaries, affiliates, parent entities, divisions, joint ventures, directors, members, officers, executives, employees, agents, representatives, attorneys and stockholders, and any and all employee benefit plans maintained by any of the above entities and their respective plan administrators, committees, trustees and fiduciaries individually and in their representative capacities, and its and their respective predecessors, successors and assigns (both individually and in their representative capacities) (collectively, the "<u>Released Parties</u>" and each a "<u>Released Party</u>"), from any and all actions, causes of action, covenants, contracts, claims, cross-claims, counter-claims, charges, demands, suits, debts, controversies, losses and liabilities whatsoever, which I or my heirs, executors, administrators, successors or assigns ever had, now have or may have arising prior to or on the date upon which I execute this Release ("<u>Claims</u>"), including any Claims arising out of or relating in any way to my employment with the Company and any of the Released Parties and any of its or their affiliates through the date upon which I execute this Release or end my employment with the Company and its affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.By signing this Release, I am providing a complete waiver of all Claims that may have arisen, whether known or unknown, up until and including the date upon which I execute this Release. This includes, but is not limited to Claims under or with respect to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.any and all matters arising out of my employment by the Company or any of the Released Parties through the date upon which I execute this Release and the cessation of said employment, and including, but not limited to, any alleged violation of the National Labor Relations Act ("NLRA"), any claims for discrimination of any kind under the Age Discrimination in Employment Act of 1967 ("ADEA") as amended by the Older

------

Workers Benefit Protection Act ("OWBPA"), Title VII of the Civil Rights Act of 1964 ("Title VII"), Sections 1981 through 1988 of Title 42 of the United States Code, Executive Order 11246, the Equal Pay Act, the Employee Retirement Income Security Act of 1974 ("ERISA") (except for vested benefits which are not affected by this agreement), the Americans With Disabilities Act of 1990, as amended ("ADA"), the Rehabilitation Act of 1973, the Fair Labor Standards Act ("FLSA"), the Fair Credit Reporting Act, the Occupational Safety and Health Act ("OSHA"), the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"), the American Rescue Plan Act, the Federal Family and Medical Leave Act ("FMLA"), the Federal Worker Adjustment Retraining Notification Act ("WARN"), the Uniformed Services Employment and Reemployment Rights Act ("USERRA");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.the Genetic Information Nondiscrimination Act of 2008; the United States, Pennsylvania or New Jersey Constitutions; any Executive Order or other order derived from or based upon any federal regulations; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.the Pennsylvania Human Relations Act, the Pennsylvania Equal Pay Act, the Pennsylvania Minimum Wage Act, as amended, the Pennsylvania Wage Payment and Collection Law, the Philadelphia Promoting Healthy Families and Workplaces Ordinance, the Philadelphia Public Health Emergency Leave Ordinance, the Philadelphia Notification of Intention to Close or Relocate Operations Ordinance, the Philadelphia Fair Practices Ordinance, the Philadelphia Unlawful Credit Screening Practices in Employment Ordinance, the Philadelphia prohibition on Testing for Marijuana as a condition of Employment, the Philadelphia Fair Criminal Records Screening Standards Ordinance, the Philadelphia Entitlement to Leave Due to Domestic or Sexual Violence Ordinance, the Pennsylvania Statutory Provision Regarding Retaliation/Discrimination for Filing a Workers' Compensation Claim;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.The New Jersey Law Against Discrimination; the New Jersey Civil Rights Act; the New Jersey Family Leave Act as amended, including the New Jersey Security and Financial Empowerment Act, the New Jersey Family Leave Insurance law, the New Jersey Earned Sick Leave Law, the New Jersey Worker Freedom From Intimidation Act; the New Jersey State Wage and Hour Law (as amended), the New Jersey Minimum Wage Law (as amended), the New Jersey Wage Theft Act, the New Jersey Wage Payment Law,; the Millville Dallas Airmotive Plant Job Loss Notification Act; the New Jersey Conscientious Employee Protection Act; the New Jersey Equal Pay Law Act (as amended, including the Diane B. Allen Equal Pay Act);), the New Jersey Occupational Safety and Health Law; the New Jersey Smokers' Rights Law; the New Jersey Genetic Privacy Act; the New Jersey Fair Credit Reporting Act; the New Jersey Cannabis Regulatory, Enforcement Assistance and Marketplace Modernization Act the New Jersey Statutory Provision Regarding Retaliation/Discrimination for Filing a Workers' Compensation Claim; New Jersey laws regarding Political Activities of Executives, Lie Detector Tests, Jury Duty, Employment Protection, and Discrimination; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e.any other federal, state or local civil or human rights law, or any other alleged violation of any local, state or federal law, regulation or ordinance, and/or public policy, implied or express contract, fraud, negligence, estoppel, defamation, infliction of emotional distress or other tort or common-law claim having any bearing whatsoever on the terms and conditions and/or cessation of my employment with the Company or any of the Released Parties, including, but not limited to, all claims for any compensation including salary, back wages, front pay, bonuses or awards, incentive compensation, performance-based grants or awards, severance pay, vacation pay, stock grants, stock unit grants, stock options, or any other form of equity award, fringe benefits, disability benefits, severance benefits, reinstatement, retroactive seniority, pension benefits, contributions to 401(k) plans, or any other form of economic loss; all claims for personal injury, including but not limited to physical injury, mental anguish, emotional distress, pain and suffering,

------

embarrassment, humiliation, damage to name or reputation, interest, liquidated damages, compensatory, exemplary, and punitive damages; and all claims for costs, expenses, and attorneys' fees.

Executive further acknowledges that Executive later may discover facts different from or in addition to those Executive now knows or believes (or knows or believes upon execution of this Release) to be true regarding the matters released or described in this Release, and even so Executive agrees that the releases and agreements contained in this Release shall remain effective in all respects notwithstanding any later discovery of any different or additional facts.

Executive represents that Executive has made no assignment or transfer of any right or Claim released herein and further agrees that he is not aware of any such right or Claim.

This Release shall not, however, apply to any obligations of the Company under the terms and subject to the conditions expressly set forth in the Agreement (claims with respect thereto, collectively, "<u>Excluded Claims</u>"). Executive acknowledges and agrees that, except with respect to Excluded Claims, the Company and the Released Parties have fully satisfied any and all obligations whatsoever owed to Executive arising out of his employment with the Company or any of the Released Parties through the date upon which Executive executes this Release and the cessation of his employment with the Company or any of the Released Parties and that no further payments or benefits are owed to Executive by the Company or any of the Released Parties. This Paragraph 1 shall in all respects be subject to Paragraph 9 of this Release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Executive understands and agrees that he would not receive the payments and benefits specified in Section 2(b) of the Agreement, except for his execution of this Release and his satisfaction of his obligations contained in the Agreement and this Release, and that such consideration is greater than any amount to which he would otherwise be entitled. Nothing in this Release shall release or impair (x) any right that cannot be waived by private agreement under the law, including but not limited to, any claim for workers' compensation or unemployment insurance benefits; (y) any vested rights under any pension or 401(k) plan; or (z) any right to enforce the Agreement or this Release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;As of the date upon which Executive executes this Release, which shall be no earlier than the Separation Date, as defined in the Agreement, Executive acknowledges that he does not have any current charge, complaint, grievance or other proceeding against the Company or any of the Released Parties pending before any local, state or federal agency regarding his employment or separation from employment. This Paragraph 3 shall in all respects be subject to Paragraph 9 of this Release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;The Company and Executive acknowledge that Executive cannot waive his right to file a charge, testify, assist, or participate in any manner in an investigation, hearing, or proceeding under the federal civil rights laws or federal whistleblower laws. Therefore, notwithstanding the provisions set forth herein, nothing contained in the Agreement or this Release is intended to nor shall it prohibit Executive from filing a charge with, or providing information to, the United States Equal Employment Opportunity Commission ("<u>EEOC</u>"), the National Labor Relations Board, the Securities and Exchange Commission, the Occupational Safety and Health Administration, or any other federal, state or local agency or from participating or cooperating in any investigation or proceeding conducted by these or other governmental agencies, including providing documents or other information, or from exercising his rights under Section Seven of the National Labor Relations Act to engage in joint activity with other employees, to the extent required or permitted by law. By signing this Release,

------

Executive is waiving rights to individual relief based on claims asserted in any such charge or complaint, or asserted by any third party on Executive's behalf, except where such a waiver of individual relief is prohibited, and except for any right the Executive may have to receive a payment from any government agency, and not the Company or any Released Parties, for information provided to the government agency. Although the parties may have agreed to keep the settlement and underlying facts confidential, such a provision in an agreement is unenforceable against the employer if the employee publicly reveals sufficient details of the claim so that the employer is reasonably identifiable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;As of the date upon which Executive executes this Release, Executive affirms that he has not knowingly provided, either directly or indirectly, any information or assistance to any party who may be considering or is taking legal action against the Company or any of the Released Parties with the purpose of assisting such person in connection with such legal action. Executive understands that if this Agreement and Release were not signed, he would have the right to voluntarily provide information or assistance to any party who may be considering or is taking legal action against the Company or any of the Released Parties. Executive hereby waives that right and agrees that he will not provide any such assistance other than the assistance in an investigation or proceeding conducted by the EEOC or other federal, state or local agency, or pursuant to a valid subpoena or court order. This Paragraph 5 shall in all respects be subject to Paragraph 9 of this Release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;Executive agrees, in addition to obligations set forth in the Agreement, to cooperate with and make himself available to the Company or any of its successors (including any past or future subsidiary of the Company), Released Parties, or its or their General Counsel, as the Company may reasonably request, to assist in any matter, including giving truthful testimony in any litigation or potential litigation, over which Executive may have knowledge, information or expertise. Executive shall be reimbursed, to the extent permitted by law, any reasonable costs associated with such cooperation, provided those costs are pre-approved by the Company prior to Executive incurring them. Executive acknowledges that his agreement to this provision is a material inducement to the Company to enter into the Agreement and to pay the consideration described herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;As of the date upon which Executive executes this Release, Executive acknowledges and confirms that he has returned all Company property to the Company including, but not limited to, all Company confidential and proprietary information in his possession, regardless of the format and no matter where maintained. Executive also certifies that all electronic files residing or maintained on any personal computer devices (thumb drives, tablets, personal computers or otherwise) will be returned and no copies retained. Executive also has returned his identification card, and computer hardware and software, all paper or computer based files, business documents, and/or other business records or office documents, as well as all copies thereof, credit and procurement cards, keys and any other Company supplies or equipment in his possession. In addition, as of the date upon which Executive executes this Release, Executive confirms that there are no business related expenses for which he will seek personal reimbursement and any amounts he owes to the Company have been paid. This Paragraph 7 shall in all respects be subject to Paragraph 9 of this Release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;Executive acknowledges and agrees that in the event Executive has been reimbursed for business expenses which were in fact personal expenses, Executive

------

shall promptly pay any such amounts within seven (7) days after any request by the Company and, in addition, the Company has the right and is hereby authorized to deduct the amount of any unpaid charge card or credit card bill from the severance payments or otherwise suspend payments or other benefits in an amount equal to such expenses without being in breach of the Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise set forth in Paragraph 4 of this Release and notwithstanding any provision to the contrary in this Release or in the Agreement, nothing contained in this Release or in the Agreement is intended to nor shall it limit or prohibit Executive, or waive any right on his part, to initiate or engage in communication with, respond to any inquiry from, otherwise provide information to or obtain any monetary recovery from, any federal or state regulatory, self-regulatory, or enforcement agency or authority, as provided for, protected under or warranted by applicable law, in all events without notice to or consent of the Company. Nothing in this Release or in the Agreement is intended to have the purpose or effect of concealing details relating to a claim of harassment, discrimination or retaliation. Executive understands that he will not be held criminally or civilly liable under any federal or state trade secret law for his disclosure of a trade secret that is made by Executive: (a) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (b) in a complaint or other document filed by the Executive in a lawsuit or other proceeding, on the condition that such filing is made under seal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;Executive agrees that neither the Agreement nor this Release, nor the furnishing of the consideration for this Release, shall be deemed or construed at any time for any purpose as an admission by the Company or any of the Released Parties of any liability or unlawful conduct of any kind, which the Company and Released Parties deny.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;Executive acknowledges and agrees that all Released Parties are third-party beneficiaries of this Release and have the right to enforce this Release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;No amendment to or waiver of this Release or any of its terms will be binding unless consented to in writing by the Executive and an authorized representative of the Company. No waiver by any Released Party of a breach of any provision of this Release, or of compliance with any condition or provision of this Release to be performed by the Executive, will operate or be construed as a waiver of any subsequent breach with respect to any other Released Party or any similar or dissimilar provision or condition at the same time or any subsequent time. The failure of any Released Party to take any action by reason of any breach will not deprive any other Released Party of the right to take action at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;If any term or provision of this Release is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Release or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision of this Release is invalid, illegal or unenforceable, this Release shall be enforceable as closely as possible to its intent of providing the Released Parties with a full release of all legally releasable claims through the date upon which the Executive executes this Release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Executive understands that he has twenty-one (21) calendar days within which to consider this Release before signing it. The twenty-one (21) calendar day period shall begin on July 9, 2025, the day after it is presented to Executive. After signing this

------

Release, Executive may revoke his signature within seven (7) calendar days ("<u>Revocation Period</u>"). In order to revoke his signature, Executive must deliver written notification of that revocation marked "personal and confidential" to AdvanSix Inc., General Counsel, 300 Kimball Drive, Suite 100, Parsippany, NJ 07054. Notice of such revocation must be received within the Revocation Period. Executive understands that neither this Release nor the Agreement will become effective or enforceable until this Revocation Period has expired and there has been no revocation by Executive, and the other terms and conditions of this Release and the Agreement have been met by Executive to the Company's satisfaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;The Company's obligations set forth in Section 2(b) of the Agreement are expressly contingent upon Executive's execution of this Release within twenty-one (21) days following July 9, 2025 and his non-revocation of his executed Release. If Executive does not execute this Release or if Executive revokes his executed Release, the Agreement and this Release shall remain in full force and effect, but neither the Company nor Executive shall have any rights or obligations under Section 2(b) of the Agreement. Provided that Executive does not revoke his executed Release, the release shall become effective on the eighth (8th) calendar day after the date on which Executive executes the signature page of this Release.

EXECUTIVE HAS READ AND FULLY CONSIDERED THIS RELEASE, HE UNDERSTANDS IT AND KNOWS HE IS GIVING UP IMPORTANT RIGHTS, AND IS DESIROUS OF EXECUTING AND DELIVERING THIS RELEASE. EXECUTIVE UNDERSTANDS THAT THIS DOCUMENT SETTLES, BARS AND WAIVES ANY AND ALL CLAIMS HE HAD OR MIGHT HAVE AGAINST THE COMPANY OR ANY OF THE RELEASED PARTIES AND THEIR AFFILIATES; AND HE ACKNOWLEDGES THAT HE IS NOT RELYING ON ANY OTHER REPRESENTATIONS, WRITTEN OR ORAL, NOT SET FORTH IN THIS RELEASE OR THE AGREEMENT. HAVING ELECTED TO EXECUTE THIS RELEASE, TO FULFILL THE PROMISES SET FORTH HEREIN AND IN THE AGREEMENT, AND TO RECEIVE THEREBY THE SUMS AND BENEFITS SET FORTH IN THE AGREEMENT, EXECUTIVE FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, EXECUTES AND DELIVERS THIS RELEASE.

EXECUTIVE HAS BEEN ADVISED OF HIS RIGHT TO CONSULT WITH HIS LEGAL COUNSEL PRIOR TO EXECUTING THIS RELEASE AND THE AGREEMENT.

IF THIS DOCUMENT IS RETURNED EARLIER THAN 21 DAYS, THEN EXECUTIVE ADDITIONALLY ACKNOWLEDGES AND WARRANTS THAT HE HAS VOLUNTARILY AND KNOWINGLY WAIVED THE 21-DAY REVIEW PERIOD, AND THIS DECISION TO ACCEPT A SHORTENED PERIOD OF TIME IS NOT INDUCED BY THE COMPANY THROUGH FRAUD, MISREPRESENTATION, A THREAT TO WITHDRAW OR ALTER THE OFFER PRIOR TO THE EXPIRATION OF THE 21 DAYS, OR BY PROVIDING DIFFERENT TERMS TO EXECUTIVE IF HE SIGNS THIS RELEASE PRIOR TO THE EXPIRATION OF SUCH TIME PERIOD.

THEREFORE, the Executive voluntarily and knowingly executes this Release as of the date set forth below.

<u>/s/ Siddharth Manjeshwar</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Siddharth Manjeshwar

Date Signed: July 13, 2025

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATIONS**

I, Erin N. Kane, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of AdvanSix Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 7, 2025

---

| |
|:---|
| /s/ Erin N. Kane |
| Erin N. Kane |
| President and Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATIONS**

I, Christopher Gramm, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of AdvanSix Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 7, 2025

---

| |
|:---|
| /s/ Christopher Gramm |
| Christopher Gramm |
| Vice President and Interim Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of AdvanSix Inc. (the "Company") on Form 10-Q for the period ended September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge:

1.&nbsp;&nbsp;&nbsp;&nbsp;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: &nbsp;&nbsp;&nbsp;&nbsp;November 7, 2025

---

| |
|:---|
| /s/ Erin N. Kane |
| Erin N. Kane |
| President and Chief Executive Officer |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of AdvanSix Inc. (the "Company") on Form 10-Q for the period ended September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.&nbsp;&nbsp;&nbsp;&nbsp;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:&nbsp;&nbsp;&nbsp;&nbsp;November 7, 2025

---

| |
|:---|
| /s/ Christopher Gramm |
| Christopher Gramm |
| Vice President and Interim Chief Financial Officer |

---

<br>